Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Trends in antiviral strategies

9.1 The challenge

There is no general procedure that can effectively prevent or control viral infections, at least based on the strategies developed over the last century and a half: vaccination, immunotherapy, chemotherapy, or their combinations. One of the main reasons is that each pathogenic virus to be controlled has some unique features in its complex and multifaceted interaction with the host cell. Not only for viruses but also cellular pathogens (bacteria, fungi, and protozoa) it is amply recognized that current practices for prevention and treatment have clear limitations. One of the difficulties arises from the potential for variation and evolution of viral and cellular pathogens that can jeopardize control strategies. For many decades there has been limited awareness of the adaptive potential of pathogens, and preventive and therapeutic designs were implemented ignoring evolution. Different experts have expressed the need to search for new paradigms to approach infectious disease, with the incorporation of Darwinian principles together with concepts from evolutionary ecology, and considering also re-implementation of old methods, such as passive antibody therapy (Casadevall, 1996; Stearns, 1999; Williams, 2009; Casadevall and Pirofski, 2015). Only very
recently, the adaptive potential of pathogens, in particular, viral quasispecies dynamics, with its conceptual extensions to other pathogenic entities (Chapter 10) have been considered as an aspect of the disease control problem.

The challenge to be confronted is symbolically portrayed in Fig. 9.1, using one of the ways to depict viral quasispecies throughout this book (lines to represent genomes and symbols on the lines to represent mutations). About 100 million sheets (!) similar to the one shown in the figure are necessary to represent the hepatitis C virus (HCV) genomes found in an acutely infected human liver at a given time point. The precise number, types, and distribution of mutations among genomes varies not only among patients but also as a function of time in each patient. A few minutes later, a slightly different image will be produced, with relative proportions of different genomes and the mutational pattern modified. This statement is an inference from replicative and mutational parameters determined in experimental systems, but comparisons of genome composition at short-time intervals (seconds, minutes, hours) are needed to define the extent of short-term variations. The dynamic mutant cloud here drawn on the basis of estimated HCV population numbers (and probably with an underrepresentation of the number of mutations per genome!) is equally applicable to the majority of RNA viruses and error-prone DNA viruses. It should be quite obvious to the reader of previous chapters that there is a nonzero probability that mutations present in the mutant spectrum may contribute to drug resistance, immune evasion, or fitness enhancement. Even if they are hidden as a tiny minority, they are ready to be selected. The challenge is clear.

FIGURE 9.1  A scheme of quasispecies intended to stress the challenge of controlling the replication of an immense and diverse entity. Each horizontal line represents a viral genome and symbols on the lines symbolize mutations, in a typical depiction of quasispecies used throughout the book. The discontinuous lines represent genomes with five or six mutations considered in this example a sufficient number to severely decrease fitness. Their fate is to attain very-low-frequency levels or be eliminated from the evolving population. About 100 million of displays similar to the one shown in this page are needed to depict the hepatitis C viral genomes present in an individual acutely infected with the virus.
9.1.1 Virus as moving targets

The potential deleteriousness of mutational load (excessive number of mutations in the same genome) is symbolized in Fig. 9.1 by the genomes drawn as discontinuous lines that contain five mutations, here, assumed to be a sufficiently large number to decrease fitness, and correspondingly, the frequency of their potential descendants in subsequent replication rounds when the five mutations are maintained. Quasispecies dynamics imposes, however, that those genomes that move from a high-frequency to a low-frequency level be replaced by newly arising mutants that display higher fitness. The mutant cloud is highly dynamic with newly arising genomes incessantly exposed to the scrutiny of selection and the lottery of random drift. The image portrayed here through mutations is even more complex if we add recombination and genome segment reassortment in the case of viruses with segmented or multipartite genomes (Chapters 2 and 3). From the point of view of antiviral interventions, viruses are true “moving targets,” in the sense that the repertoire of variants that we should inhibit at a one-time point is not exactly the same to be inhibited at a subsequent time point. The difference may be irrelevant regarding the efficacy of antiviral treatment, or it may not. The impact of the dynamic change cannot be anticipated since mutations that compromise antiviral efficacy arise in an unpredictable way. Applied to clinical practice, it means that a specific inhibitor combination may be effective for many infected individuals for a long time, or only for a few individuals for a short time, with a range of possible intermediate outcomes. The new antiviral strategies discussed in this chapter take into consideration the moving target feature of the viruses to be controlled, and they have been proposed by an increasing number of experts aware of the quasispecies challenge.

9.2 Practiced and proposed strategies to confront the moving target challenge with antiviral inhibitors

The basic statistical considerations that justify the need to use multiepitopic vaccines to protect against variable viruses characterized by quasispecies behavior (keep in mind Fig. 9.1) were discussed in Section 8.3 of Chapter 8. In the present chapter, we focus on pharmacological approaches based on the administration antiviral inhibitors; immunotherapy is mentioned as a potential ingredient of combination therapies with antiviral inhibitors.

The systematic selection of drug (or multidrug)-resistant mutants in viral populations has encouraged the design of antiviral strategies intended to avoid viral breakthrough and treatment failure. The main options in clinical practice or under investigation using nonmutagenic and mutagenic antiviral inhibitors are summarized in Box 9.1. None of the listed strategies is totally free of the problem of selection of drug-resistant mutants, but the proposals are intended to avoid or delay such selection. Next, we discuss the major features of each of the six suggestions listed in Box 9.1.

9.2.1 Combination treatments

Studies on the advantage of the combined administration of two drugs were pioneered by H.J. Eggers and I. Tamm as part of their studies with picornaviruses (Eggers and Tamm, 1963; Eggers, 1976). Combination therapy applied to human immunodeficiency virus type 1 (HIV-1) has been the great success for the control of acquired immunodeficiency syndrome (AIDS) that has drastically reduced AIDS-related mortality. This type of treatment for HIV-1 is termed highly active antiretroviral therapy (HAART), and it is implemented with three (sometimes
two) different antiretroviral agents. HAART efficacy has steadily improved due to the availability of new inhibitors directed to different HIV-1 targets, with application to rescue treatments (Gandhi et al., 2019). Success is only partial due to side effects (that may be derived from off-target activities of the drugs), incomplete patient adherence to the treatment, selection of multidrug-resistant viral variants, and above all, to the retroviral nature of HIV-1 that renders virus extinction from the organism a difficult endeavor. In retroviruses and hepadnaviruses, the viral DNA is not only hidden from antiviral drugs, but it can serve as an archive of genomes whose replication can be reactivated upon treatment discontinuation. If combination therapy could be coupled with an efficient elimination of the proviral reservoirs in host DNA (De Crignis and Mahmoudi, 2014; Sadowski and Hashemi, 2019), HIV-1 could probably be eliminated from the infected organism, as achieved in the case of HCV infections in many patients treated with direct-acting antiviral agents (DAAs).

The general advantage of combination therapy over monotherapy is largely a consequence of quasispecies dynamics, and it has been amply evidenced by clinical practice, and supported by straightforward statistical considerations and theoretical models of virus dynamics (Domingo, 1989; Domingo and Holland, 1992; Ho, 1995; Bonhoeffer et al., 1997; Pol et al., 1999; Ribeiro and Bonhoeffer, 2000; Le Moing et al., 2002; Van Vaerenbergh et al., 2002; Domingo et al., 2008; Müller and Bonhoeffer, 2008; Nijhuis et al., 2009) (see also Section 8.4 in Chapter 8). Furthermore, use of combination therapies conforms to the “hit early, hit hard” dictum of P. Ehrlich and D.D. Ho, explained in Section 8.10 of Chapter 8. There is the misconception (among some experts, but mainly among politicians!) that only patients in advanced phases of a viral infection (i.e., only precirrhotic or cirrhotic patients infected with HCV) should be treated aggressively with drug combinations. This is not what evolutionary virology teaches us: patients should be treated as strongly as possible and as early as possible, provided side effects can be controlled. Viruses should be given no chance to walk in sequence space in search of adaptive pathways (Chapter 3). Adequate combination treatments can fulfill such purpose.

9.2.2 Split treatments

A second proposed strategy is to divide an antiviral treatment into two steps: first an induction,
and then a maintenance step (von Kleist et al., 2011). It is based on a theoretical model developed to confront HIV-1 infections. The key argument is that when a treatment has to be changed due to virus rebound, mutants resistant to the ineffective drug have had the opportunity to replicate in the patient, increasing the viral load and supplying a proviral archive with inhibitor-resistant latent viruses, thus excluding the drug as a component of future combination treatments. The induction regimen should be followed by a maintenance regimen at a point in time in which the second drug finds a low viral load and limited numbers of mutants resistant to the initial treatment. Critical issues for the implementation of this proposal are the timing of treatment switch, the decrease of viral load as a result of the induction regimen, and the genetic and phenotypic barriers to the maintenance regimen. Clinical trials are needed to explore this interesting proposal, which is of potentially broad applicability.

9.2.3 Targeting cellular functions

Many cellular functions are needed to complete any step of a virus replication cycle. A good deal of research in virology has as its main objective to identify and characterize cellular functions that participate in virus entry into the cell, intracellular multiplication, release from cells, or in the immune response. Since cellular proteins cannot vary in response to the presence of an inhibitor (at least for common cell types within the time frame of a viral infection), an obvious thought is to administer inhibitors of those cellular functions (often proteins) that are needed to sustain viral replication; such inhibitors should suppress viral replication without selection of inhibitor-resistant mutants (Geller et al., 2007; Hopkins et al., 2010; Garbelli et al., 2011; Kumar et al., 2011; Vidalain et al., 2015; Hover et al., 2017; de Wilde et al., 2018; Ong et al., 2018). Despite potential benefits, two major problems may be encountered with antiviral agents directed to cellular proteins: (i) toxic effects derived from suppression or alteration of cellular activities in which the target protein is involved, and (ii) selection of viral mutants that are insensitive to the presence of the inhibitor, despite the inhibitor not being directed to viral components. Insensitivity may come about by at least three different mechanisms. If the cellular protein which is the target of the inhibitor forms a complex with a viral protein in the course of viral replication, amino acid substitutions in the viral protein may permit progression of the infection in the presence of the inhibitor. This is the case of HCV resistance to the nonimmunosuppressive cyclophilin inhibitor SCY-635. NS5A interacts with cyclophilins and with NS5B; amino acid substitutions in NS5A (T17A, E295K, and V44A) and in NS5B (T77K and I432V) decrease the sensitivity of the virus to SCY-635, although the precise molecular mechanism of resistance has been debated (Chatterji et al., 2010; Sarrazin and Zeuzem, 2010; Delang et al., 2011; Kwong et al., 2011; Vermehren and Sarrazin, 2011).

Development of resistance may be host cell-dependent, as documented with poliovirus resistance to brefeldin A, a drug that targets a cellular guanine nucleotide exchange factor found in the replication complex. Resistant mutants were selected in HeLa cells but not in Vero cells; the degree of resistance of poliovirus mutants differed among cells of human origin, and resistance inflicted a fitness cost upon the virus (Viktorova et al., 2015).

When inhibitors are targeted to the cellular receptor for a virus, mutants may be selected that can enter cells through an alternative receptor. This has been documented with HIV-1 that can use coreceptor CCR5, CXCR4, or both (dual-tropic viruses). A modified RANTES [regulated on activation, normal T cell expressed, and secreted; also termed as chemokine (C–C motif) ligand 5 or CCL5] selected coreceptor switch variants in a SCID (severe combined immunodeficiency) mouse model (Mosier et al., 1999). The mutants with amino acid substitutions in loop
V3 of Env protein were selected to use CXCR4 rather than CCR5 as a coreceptor (see also Section 4.4 in Chapter 4). V3 loop mutants associated with maraviroc resistance may exhibit increase replicative capacity (Garcia-Perez et al., 2015).

An alternative mechanism to overcome the inhibition of a cellular protein is that viral mutants are selected that can utilize the cellular protein in complex with the inhibitor. This is the case of HIV-1 mutants resistant to small coreceptor CCR5-binding inhibitors; mutants with amino acid substitution in the V3 loop region or elsewhere in Env can use either free or inhibitor-bound CCR5 to enter cells, with an efficiency that depends on the CCR5 expression level and the host cell type (Pugach et al., 2007, 2009). These examples illustrate the multiple pathways that viruses can exploit to overcome inhibitors directed to cellular proteins. They constitute additional evidence that “abundant sources of genetic variation exist for viruses to learn new tricks, …” emphasized by J. Lederberg in connection with viral disease emergence and reemergence (also quoted in Section 7.7.1 of Chapter 7). Since many viruses can use alternative receptors for entry into cells (Section 4.4 in Chapter 4), inhibitors directed to viral receptors may promote the selection of virus subpopulations that can use a different receptor.

9.2.4 Use of drugs that stimulate the host innate immune system

Some inhibitors of enzymes of the de novo pyrimidine biosynthesis pathway (DD264, bequinar, and A3) stimulate the innate immune response and behave as broad-spectrum antiviral inhibitors (Lucas-Hourani et al., 2013; Munier-Lehmann et al., 2015; Vidalain et al., 2015). The observed effect is one among other connections that have been established between nucleotide and DNA metabolism and immune stimulation (Motani et al., 2015). For some of the pyrimidine biosynthesis inhibitors, additional mechanisms of antiviral activity might be involved, as in the inhibition of lymphocytic choriomeningitis virus (LCMV) replication and transcription by A3 (Ortiz-Riano et al., 2014). Stimulation of the innate immune response may restrict the selection of escape mutants because the virus must mutate at several sites to overcome the different branches of the response, as is the case with interferon (IFN) resistance (Perales et al., 2014). Multifactorial antiviral responses increase the genetic and phenotypic barriers to resistance (Section 8.4.2 in Chapter 8).

9.2.5 Combined use of immunotherapy and chemotherapy

An extension of the advantage of combination therapy to decrease the selection of antiviral-resistant mutants consists in the combined use of immunotherapy (administration of neutralizing antibodies or other means of immune stimulation, such as vaccination) together with antiviral inhibitors. The concept was pioneered by R.G. Webster and colleagues and was proposed as a strategy for the control of influenza viruses (Webster et al., 1985). The authors showed that the simultaneous administration of inactivated H5N2 vaccine and the inhibitor amantadine conferred protection against H5N2 influenza virus A/Chick/Pennsylvania/83 in chickens (Webster et al., 1986). Related notions have been investigated with other viruses and different components of the immune response (Seiler et al., 2000; Li et al., 2005). However, additional model in vivo experiments with animals and clinical trials with patients are necessary to investigate the effectiveness of combined immunotherapeutic approaches, in line with related research in cancer therapy (Dalgleish, 2015).

As a general outlook on the strategies summarized in previous sections, the potential of combining two (or even more) of the proposals listed in Box 9.1 is encouraging, provided off-target effects of drugs or immune interventions
can be controlled and side effects minimized. A trend toward “complex” treatment protocols is the expected response to the adaptive capacity of viral quasispecies. The introduction of mutagenic agents in antiviral designs is an important departure that exploits one of the corollaries of quasispecies behavior: the error threshold relationship (introduced in Section 3.6.3 of Chapter 3). It is the basis of lethal mutagenesis discussed next.

9.3 Lethal mutagenesis and the error threshold

Lethal mutagenesis is defined as the process of viral extinction due to an excess of mutations in the viral genome. J.J. Holland and colleagues pioneered studies on the adverse effects of several chemical mutagens on the yield of infectious poliovirus (PV) and vesicular stomatitis virus (VSV) in cell culture (Holland et al., 1990). The term lethal mutagenesis was first proposed by L. Loeb, J.I. Mullins, and colleagues in a study of the loss of replicative potential of HIV-1 upon multiplication in human CEM cells in the presence of the deoxynucleoside analog 5-hydroxydeoxycytidine (5-OH-dC) (Loeb et al., 1999). The experimental design of lethal mutagenesis was inspired in the error threshold relationship derived from the basic equation of quasispecies dynamics (Eigen and Schuster, 1979; Swetina and Schuster, 1982; Nowak and Schuster, 1989; Schuster, 2016). Initially elaborated on simple (single peak) fitness landscapes, quasispecies theory has as one of its main corollaries that the stability of genetic information during a replicative process is dependent on two parameters: the error rate during replication and the amount of genetic information to be maintained. The basic equations that describe the relationship between the maximum tolerable mutation rate ($\mu_{\text{max}}$) to ensure the transfer of genetic information to the next generations of genomes with length $n$, are included in Fig. 9.2. They are relevant to the application of the error threshold concept to virology (Eigen, 2002; Schuster, 2016). In the equations, an important variable is the superiority of the master sequence over its surrounding mutant spectrum, denoted by $\sigma_m$. Consistent with $\sigma_m$ being in the numerator of the equations, virologists will intuitively understand that a high superiority of the dominant sequence reinforces the stability position of the population (dominant or master sequence together with its surrounding mutant cloud) in that environment, and in the absence of external perturbations. A larger mutational input is necessary to destabilize the distribution and drive the mutant spectrum toward extinction.

There are additional factors that can modify the stability of a mutant distribution and the position of the error threshold; the mathematical justification and practical implications for virology have been detailed (Schuster, 2016). Of particular relevance to a virus population stability is the influence of the fitness landscape in the maintenance of genetic information. The first noteworthy result of the theoretical studies is that an error threshold is present in realistic, rugged fitness landscapes, as those proposed to best describe viruses on the basis of experimental evidence (see also Section 5.3 in Chapter 5). Second, the position of the error threshold moves toward lower mutation rates when the ruggedness of the fitness landscape (represented by a parameter that consists of a band of fitness values) is increased. How replication of viruses in variable fitness landscapes (e.g., under variable environmental conditions) versus a constant environment may affect the ease of extinction by increased mutagenesis is a largely unexplored question.

9.3.1 Reconciliation of theory and experiment: a proposal

Several theoretical models have been presented to explain the lethal mutagenesis of viruses (review in Tejero et al., 2016). The models are conceptually diverse, and at times with
remarkably counterintuitive proposals. Some models deny a connection between the error threshold of quasispecies theory and the extinction of viruses by enhanced mutagenesis. In one of the models discussed by H. Tejero and colleagues, it was suggested that error catastrophe could not occur in the presence of lethal genotypes, a proposal that was considered peculiar by experimentalists, and that it was proven incorrect by Takeuchi and Hogeweg (2007) [see also references in that publication and in Tejero et al. (2016)]. Other models that have suggested that lethal mutagenesis is unrelated to the error threshold have defined an extinction threshold to mean the mutation rate at which a viral population goes extinct. A rather counterintuitive proposal is that the error threshold is caused by the “survival of the flattest” which means dominance of genomes with low replicative capacity and high tolerance to mutations (robustness).
that would hinder virus extinction (Tejero et al., 2011) (see Section 5.7 in Chapter 5 on the advantage of the flattest in a fitness landscape).

C. Perales and I have carefully reviewed the main experimental results obtained in our and other laboratories on the molecular events that accompany the transition toward virus extinction and have tried to harmonize the experimental observations with the most realistic and significant theoretical models reviewed by Tejero et al. (2016). The mainstream of experimental results can be summarized as follows. The first studies that were an extension of those carried out in J.J. Holland’s laboratory confirmed a connection between a mutagenic activity and decrease of viral infectivity and showed that low viral load and low viral fitness favored virus extinction (Loeb et al., 1999; Sierra et al., 2000). (That low population numbers increase the risk of extinction is accepted for any type of organism under any circumstance, and it is known as the Alee effect). Then, following the important discovery that the nucleoside analog ribavirin (1-β-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide) is mutagenic for PV (Crotty et al., 2000) it was observed that ribavirin decreased PV-specific infectivity (the ratio of infectivity to the amount of viral RNA) (Crotty et al., 2001). A decrease of specific infectivity, together with an increase of mutation frequency, is now considered the standard way to distinguish lethal mutagenesis from mere inhibition (Box 9.2). [This is not to mean that decreases of specific infectivity are exclusive of lethal mutagenesis. They have also been documented as a result of codon deoptimization (Section 4.3 of Chapter 4) and in viral clones subjected to many plaque-to-plaque transfers (Section 6.5.2 in Chapter 6)].

In a subsequent study, A. Grande-Pérez and colleagues documented that treatment of cells persistently infected with LCMV with 5-fluorouracil [5-Fluoro-1H,3H-pyrimidine-2,4-dione (FU)] resulted in a decrease of infectivity that preceded the decrease of viral RNA (see Section 9.4 for the mutagenic mechanisms of ribavirin and FU). This result suggested that a class of replication-competent RNA that did not lead to infectious virus was generated during the

---

**BOX 9.2**

**Main observations on viral extinction by mutagenic agents**

- Low viral load and low viral fitness favor extinction.
- During the transition toward extinction, the viral population:
  - Decreases its specific infectivity.
  - Increases its mutant spectrum complexity (movement toward usually unfavored regions of sequence space).
  - Maintains an invariant consensus sequence.
- Reduction in viral load per se is not the mechanism of virus extinction. A load decrease by a mutagenic agent may extinguish the virus while the same decrease with an inhibitor may not.
- Viruses displaying different replicative features respond to mutagenic agents in a very similar way: the strategy is of general applicability provided a virus-specific mutagenic agent is available.
- The use of mutagens as antiviral agents has been validated in vivo.
FU-mediated transition toward viral extinction. A theoretical model developed by S. Manrubia predicted that such defective genomes that were termed defectors were required to achieve LCMV extinction with a limited mutagenic intensity by FU (Grande-Pérez et al., 2005b). The proposal that loss of viral infectivity is due to the action of defective genomes produced by the mutagenic agent is termed the lethal defection model of virus extinction, and it is consistent with several observations on the extinction of other viruses (reviewed in Domingo et al., 2012). A diagnostic test is that loss of infectivity precedes loss of viral RNA (Fig. 9.3). Lethal defection can be regarded as an extreme outcome of interfering interactions that are exerted among components of the mutant spectrum when their mutational load increases (compare with Section 3.8 of Chapter 3).

The studies by A. Grande-Pérez, S. Manrubia, and colleagues distinguished two pathways that viruses can follow when subjected to mutagenesis: lethal defection at low mutagenic intensities, and overt lethality at high mutagenic intensities. Fig. 9.4 recapitulates our understanding of the steps involved in mutagenesis-driven virus extinction, with the important qualification that no sharp boundary exists between the lethal defection and the overt lethality phases. Studies with foot-and-mouth disease virus (FMDV) have provided further support to the lethal defection phase of extinction. Defective FMDV RNAs inhibited replication of standard FMDV RNA in a specific manner when co-electroporated into cells (Perales et al., 2007). Specificity means that the defective FMDV RNAs did not inhibit replication of the related encephalomyocarditis viral RNA. Specificity was also evidenced by the loss of interfering activity of a defector genome by the introduction of a mutation that prevented RNA replication. The requirement of replication of the defective RNAs suggests that a sufficient amount of expressed proteins is needed for interference (Perales et al., 2007). These results are consistent with enhanced and also specific interfering activity exerted by mutagenized FMDV RNA (González-López et al., 2004). Thus, the available evidence suggests that mutant RNAs—whose frequency and mutational load increase as the mutagenesis proceeds—adversely affect the
replication of nonmutated RNAs that coexist in the same replicative ensemble. This is the major molecular event that has been recognized in the lethal defection phase of Fig. 9.4.

The infectious FMDV RNA that can be retrieved from a mutagenized population by dilution and plaque isolation display decreases in replicative fitness (up to 200-fold lower infectivity) relative to the parental, nonmutagenized virus (Arias et al., 2013) associated with an eight-fold increase in mutation frequency. This result reinforces the complexity of events during lethal mutagenesis, confirms that fitness may be impaired in clones that transiently survive the mutagenic activity, and suggests an overlap between the lethal defection and overt lethality phases drawn in Fig. 9.4.

We can now consider theoretical models in light of the experimental results. First, the proposed interference by substituted, trans-acting proteins is in line with the early descriptions of fitness deterioration of cells due to the collapse of interdependent nucleic acid and protein trans networks in connection with the process of aging (Orgel, 1963). In the case of lethal defection, the effects of mutations have to be calibrated, keeping in mind the multifunctional nature of viral proteins (Section 3.8.1 in Chapter 3). When a protein is defective, it can jeopardize the activities of any other proteins that interact with it: a trans network can collapse by a domino effect. The possible influence of the topology of the network of interactions among genomes for maintenance of population stability is a largely unexplored possibility which is briefly addressed in the closing Chapter 10.

The notion that viral mutagenesis promotes drift in sequence space was shown by direct amplification of A, U-rich genomic sequences of FMDV subjected to ribavirin mutagenesis (Perales et al., 2011b). The main effect of ribavirin was to accelerate the occupation of A, U-rich regions of sequence space, presumably due to the tendency of this purine analog to produce an excess of G→A and C→U transitions (Section 9.4).

Analysis of the numbers and types of mutations suggests that the A, U-enriched portion of sequence space is detrimental to viral fitness. Movements toward unfavorable regions of sequence space are also suggested by mutant spectrum analyses of FMDV subjected to FU mutagenesis and other viruses subjected to other mutagenic agents (Grande-Pérez et al., 2002, 2005a; Agudo et al., 2008; Ortega-Prieto et al., 2013).

In view of the above evidence, any theoretical model of lethal mutagenesis that proposes a delocalization of the genome population in sequence space fits the experimental results of
extinction. Specifically, models based on the advantage of the flattest that predict the absence of extinction (Tejero et al., 2016), in reality, predict the extinction of a real virus. This is because the mutagenesis-driven, astray walk in sequence space in the absence of a dominant master sequence should produce an increased number of defective genomes (lethal defection) in unfavorable regions of sequence space (such as the A, U-rich regions promoted by ribavirin). The net result should be not only lethal defection but also an increasingly frequent hitting of lethal portions of the space (overt lethality phase shown in Fig. 9.4). Thus, any theoretical models based on genome sequence delocalization fit the experimental observations (Perales and Domingo, 2016). How such delocalization can be turned into an antiviral strategy is discussed in the next sections.

9.4 Virus extinction by mutagenic agents

The pioneer experiments by J.J. Holland and colleagues demonstrated the adverse effects of mutagenic agents—including the base analog FU and the nucleoside analog 5-azacytidine [4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one (5-AZA-C)]—on the production of infectious PV and VSV progeny (Holland et al., 1990; Lee et al., 1997). These investigations were followed by several others that examined the effect of base and nucleoside analogs on virus survival. A few studies with animal viruses are summarized in Table 9.1 to illustrate that viruses displaying diverse replicative strategies (positive- and negative-strand RNA viruses and retroviruses) are vulnerable to increases in mutation rate. The investigations in cell culture or animal hosts employ mutagenic base or nucleoside analogs which are converted intracellularly into the nucleoside-triphosphate forms. The latter can be incorporated into RNA that in the next round of template copying will give rise to misincorporations (point mutations) and in some cases to RNA chain termination. Mutagenesis is mainly due to ambiguous pairing between the mutagenic base and standard nucleotides, with the formation of Watson-Crick or wobble base pairs. Some base-pair structures of FU with A or G are drawn in Fig. 9.5 (Sowers et al., 1988; Yu et al., 1993), and of ribavirin and T-705 (favipiravir) (5-Fluoro-2-oxo-1H-pyrazine-3-carboxamide) in Fig. 9.6 (Crotty et al., 2000; Jin et al., 2013) (see Section 2.2 in Chapter 2 for the standard Watson-Crick and some wobble base pairs).

The possible point mutations generated as a consequence of FU or ribavirin incorporation during viral genome replication are depicted in Figs. 9.7 and 9.8, respectively. The figures represent the most frequent cause of the successive analog incorporation and subsequent events upon copying of positive- and negative-strand viral RNA, although the pathways are equally applicable to DNA in the case of deoxynucleotide analogs. The schemes can serve as a guide to anticipate the possible mutation types induced by other analogs provided their base-pairing behavior has been investigated by physicochemical procedures, considering that mutation preferences may be affected by environmental factors.

The mutant repertoire produced by a mutagenic nucleotide may be influenced by the structure and micro-environment of the viral polymerase in the neighborhood of the site that determines the base pairing of the template with the incoming nucleotide. Although polymerases share general structural features, nucleotide discrimination and incorporation is subtly dependent on the nature of surrounding amino acids, template-primer nucleotide sequences, or ionic composition (see Section 2.6 of Chapter 2 on polymerase structure and fidelity mutants, and Section 9.6 on interactions in viral polymerases associated with resistance to mutagenic nucleotides). For several viruses, the mutant spectra produced upon replication in the presence of FU include an excess of A → G and U → C, over G → A and C → U transitions
### TABLE 9.1 Some studies on lethal mutagenesis of viruses.

| Virus | Base or nucleoside analog | Main observations | Reference |
|-------|---------------------------|-------------------|-----------|
| DENV  | T-705                     | Several base and nucleoside analogs evaluated. Mutagenesis by T-1105 and T-1106 documented. Bias in favor of transitions | Qiu et al. (2018) |
| EBV   | T-705                     | Protection of macaques associated with mutagenic doses. Bias in favor of G → A and C → U | Guedj et al. (2018) |
| FMDV  | FU                        | Extinction favored by low viral load and low viral fitness | Sierra et al. (2000); Pariente et al. (2001) |
| FMDV  | Rib                      | Enhanced mutagenesis eliminated the virus from persistently infected cells | Airaksinen et al. (2003) |
| FMDV  | FU                        | Virus extinction required mutagenesis and not only inhibition by guanidine hydrochloride and heparin | Pariente et al. (2003) |
| FMDV  | FU                        | Extinction of a Rib-resistant mutant by the combination of FU and guanidine hydrochloride | Perales et al. (2009a) |
| FMDV  | T-705                     | New option for viral infections of veterinary impact. No obvious outstanding mutation type | De Avila et al. (2017) |
| GBvB  | Rib                      | Evidence of error-prone replication induced by Rib in cell culture, but no significant reduction of viremia in vivo (tamarin model). RTP incorporated in viral RNA can induce misincorporations and an elongation block | Lanford et al. (2001); Maag et al. (2001) |
| HCV   | Rib                      | Rib increased the mutation frequency in conserved regions of an HCV replicon genome | Contreras et al. (2002) |
| HCV   | Rib                      | Rib-mediated extinction of HCV through an increase of mutant spectrum complexity and decrease of specific infectivity | Ortega-Prieto et al. (2013) |
| HCV   | T-705                    | New option for anti-HCV treatments. Bias in favor of G → A and C → U | De Avila et al. (2016) |
| Hantaan virus | Rib          | Rib-induced high mutation frequency in S segment. A range of Rib concentrations revealed a nonlinear fit of mutation frequency and mutagen concentration | Severson et al. (2003); Chung et al. (2007) |
| HIV-1 | 5-OH-dC                  | Decrease of virus infectivity; 3-fold increase of mutation frequency, and 5.6-fold increase in G → A transitions | Loeb et al. (1999) |
| HIV-1 | 5-OH-dC                  | Efficient HIV-1 extinction by combinations of 5-OH-dC and 3′-azido-3′-deoxythymidine (AZT) | Tapia et al. (2005) |
| HIV-1 | 5-AZA-C                  | Lethal mutagenesis during reverse transcription is the main antiviral effect of 5-AZA-C, following reduction to the deoxycytidine form | Dapp et al. (2009) |
| HIV-1 | 5-AZA-C                  | Adverse effect of 5-AZA-C on viral infectivity, potentiated by the host factor APOBEC3G | Dapp et al. (2012) |
| IV    | T-705                    | First evidence that the broad-spectrum antiviral agent T-705 (favipiravir) can act as a lethal mutagen | Baranovich et al. (2013) |
| IV    | FU                       | Effective lethal mutagenesis of H3N2 and H1N1 IVs. Evidence of high barrier to resistance | Pauly and Lauring (2015) |

(Continued)
(Sierra et al., 2000; Grande-Pérez et al., 2002; Ruiz-Jarabo et al., 2003; Bassi et al., 2018; Diaz-Martínez et al., 2018; review on FU antiviral activity and mutagenesis in Agudo et al., 2009). The bias in favor of A → G and U → C mutations suggests that FU behaved as U rather than C when incorporated by the viral polymerases, and that, once FU was a template residue, it tended to behave as C as rather than U (Fig. 9.7). Studies with several viruses have indicated that ribavirin mutagenesis yields mutant spectra with an excess of G → A and C → U over A → G and U → C (Fig. 9.8), although the incorporation bias depends on the virus [(Crotty et al., 2001; Airaksinen et al., 2003; Day et al., 2005; Chung et al., 2007; Agudo et al., 2010; Moreno et al., 2011; Dietz et al., 2013; Ortega-Prieto et al., 2013; Galli et al., 2018) among other

| Virus a | Base or nucleoside analog b | Main observations | Reference |
|---------|-----------------------------|-------------------|-----------|
| LCMV FU | Largest increases in mutation frequency did not predict virus extinction. Virus extinction occurred without modification of the consensus sequence | Grande-Pérez et al. (2002, 2005a) |
| LCMV FU Rib | FU- and Rib-mediated extinction of LCMV in BHK-21 cells, associated with up to 10-fold increases of mutation frequency with FU, and inhibition of gene expression with RBV | Ruiz-Jarabo et al. (2003) |
| LCMV Rib | Mutagenic activity documented in cell culture | Moreno et al. (2011) |
| MNV T-705 | Efficient extinction in cell culture and in vivo. Bias in favor of A → G and U → C | Arias et al. (2014) |
| PV Rib | Evidence of Rib-mediated error catastrophe of PV | Crotty et al. (2001) |
| PV FU 5-AZA-C | Impairments of viral replication; 16- to 2.8-fold increases in mutation frequency | Holland et al. (1990) |
| RVFV T-705 | Lethal mutagenesis in cell culture. Prospect of new treatments for this emerging disease. Significant increase in G → A and C → U transitions | Borrego et al. (2019) |
| TMV FU | FU-mediated decrease of TMV infectivity, and increase of A → G, U → C transitions | Diaz-Martínez et al. (2018) |
| VSV FU 5-AZA-C | Impairments of viral replication; 16- to 2.8-fold increases in mutation frequency | Holland et al. (1990) |
| WNV Rib | Error-prone replication and transition to error catastrophe were dependent on the host cell line | Day et al. (2005) |
| WNV T-705 | Adds to prospects of lethal mutagenesis to combat flaviviral infections. Bias in favor of G → A and A → G, to a lesser extent U → C | Escribano-Romero et al. (2017) |
| ZIKV T-705 | FU more effective against USUV than Zika, and more converse for Rib and T-705. Bias in favor of G → A and C → U | Bassi et al. (2018) |

a The virus abbreviations are: DENV, Dengue virus; EBV, Ebola virus; FMDV, foot-and-mouth disease virus; GBvB, GB virus B; HCV, hepatitis C virus; HIV-1, human immunodeficiency virus type 1; LCMV, lymphocytic choriomeningitis virus; MNV, murine norovirus; PV, poliovirus; RFFV, Rift Valley fever virus; TMV, Tobacco mosaic virus; USUV, Usutu virus; VSV, vesicular stomatitis virus; WNV, West Nile virus; ZIKV, Zika virus.

b The abbreviations for drug names are: 5-AZA-C, 5-azacytidine; FU, 5-fluorouracil; 5-OH-dC, 5-hydroxydeoxycytidine; Rib, ribavirin; T-705, favipiravir.
studies; as reviews of the mutagenic activity of ribavirin see (Crotty et al., 2002; Beaucourt and Vignuzzi, 2014). The effect of a mutagenic nucleotide analog may be influenced by the position it occupies in the template. This was shown in the early site-directed mutagenesis experiments of bacteriophage Qβ RNA performed by R. Flavell, C. Weissmann, and colleagues (Chapter 3). When the pyrimidine analog N4-hydroxy CMP was present at the extracistronic position 15, it directed the incorporation of GMP slightly more efficiently than AMP, while at position 39 incorporation of AMP was three-fold higher than GMP (compare Flavell et al., 1974 and Domingo et al., 1976).
9.4.1 The search for new mutagenic nucleotide analogs

New mutagenic nucleotides are currently being investigated as potential lethal mutagens for viruses (Harki et al., 2002, 2006, 2007; Graci and Cameron, 2004; Beach et al., 2014; Dapp et al., 2014; Vivet-Boudou et al., 2015; among other studies). There is active research to apply drugs (or their derivatives) used in antibacterial or anticancer therapy to lethal mutagenesis (drug repositioning or drug repurposing; see Section 8.4 in Chapter 8). L.M. Mansky and his associates have pioneered such efforts for the search of new antiretroviral agents, as well as the study of new combination therapies based on lethal mutagenesis (Dapp et al., 2012, 2013; Bonnac et al., 2013; Rawson and Mansky, 2014). They studied the joint effect of 5-AZA-C and apolipoprotein B mRNA editing complex 3G (APOBEC3G) on the mutational spectrum of HIV-1. The results revealed unexpected changes in the mutational trend, particularly an increase in $G \rightarrow A$ transitions and a decrease of $G \rightarrow C$ transversions, a mutation type which is prominent with 5-AZA-C alone (Dapp et al., 2009). They have also defined a new class of antiviral agents termed “mild mutagens” that while exhibiting a limited mutagenic activity they may enhance the antiviral effect of other inhibitors (Rawson et al., 2013). It may be interesting to explore possible mild mutagenic activities for
other analogs, such as shown with sofosbuvir for Zika virus (Sacramento et al., 2017).

The complexities of the interaction among mutagens and between inhibitors and mutagens in infected cells are still poorly understood. A few studies have provided evidence that some sequential inhibitor-mutagen treatments may have an advantage over the corresponding combinations, fundamentally because they avoid interferences derived from the simultaneous presence of a mutagen and inhibitor during viral replication (Section 9.8).

9.5 Lethal mutagenesis in vivo: complications derived from multiple mechanisms of drug action—the case of ribavirin

Most of the investigations summarized in the previous section were carried out in cell culture. Some animal experiments and a clinical trial have provided proof of principle of the feasibility of antiviral interventions based on lethal mutagenesis in vivo. J.C. de la Torre and colleagues documented that administration of FU to mice prevented the establishment of a persistent LCMV infection in the animals (Ruiz-Jarabo et al., 2003). J.I. Mullins and colleagues carried out the first phase II clinical trial using lethal mutagenesis by administering KP1461 (N4-heptyloxy carbonyl-5,6-dihydro-5-aza-2'-deoxycytidine), the prodrug of KP1212 (5,6-dihydro-5-aza-2'-deoxycytidine), to HIV-1 infected volunteers previously treated with antiretroviral agents (Mullins et al., 2011). No reduction in viral load or increase in average mutation frequencies was noted in the treated patients. However, mutations that likely occurred in HIV-1 in the course of the treatment were predominantly A → G and G → A transitions, as expected from the base-pairing behavior of the pyrimidine analog. The study validated lethal mutagenesis as an antiviral approach for human disease.

The purine analog favipiravir (T-705) (6-fluoro-3-hydroxy-2-pirazinecarboxamide; base pairing behavior shown in Fig. 9.6) acted as an effective antinorovirus agent in a mouse model, with features diagnostic of lethal mutagenesis: increases of mutation frequency and decreases of specific infectivity (Arias et al., 2014) (Box 9.2). Favipiravir and derivatives are interesting compounds because they share with ribavirin a broad antiviral spectrum of activity. Favipiravir has proven effective against several viruses in vivo, including West Nile infection of mice and hamsters (Morrey et al., 2008), lethal inhalation of Rift Valley fever virus in mice (Caroline et al., 2014), and highly pathogenic H5N1 IV in mice (Kiso et al., 2010). It is still an open question if it acts as a lethal mutagen in these in vivo systems as it does with IV in cell culture (Baranovich et al., 2013) and norovirus in cell culture and in vivo (Arias et al., 2014). (Favipiravir mutagenesis is discussed in the coming Section 9.5.1).

Ribavirin was used for many years in combination with pegylated IFN-α as the standard of care treatment for HCV infections (McHutchison et al., 1998; Cummings et al., 2001; Di Bisceglie et al., 2001). It is not clear whether lethal mutagenesis is part of the anti-HCV activity of ribavirin, with some studies favoring a mutagenic activity on the virus and others not (Gerotto et al., 1999; Querenghi et al., 2001; Sookoian et al., 2001; Dixit et al., 2004; Asahina et al., 2005; Chevaliez et al., 2007; Lutchman et al., 2007; Perelson and Layden, 2007; Cuevas et al., 2009; Dietz et al., 2013). The study by Dietz et al. (2013) involved deep sequencing analyses of HCV from patients subjected to ribavirin monotherapy, and the virus showed the mutational bias expected from ribavirin mutagenesis. It has been suggested that in cell culture experiments, the concentrations of ribavirin used are not attainable in vivo. Until measurements of the concentration of ribavirin nucleotides at the HCV replication complexes are available, it cannot be concluded that
ribavirin concentrations in vivo are incompatible with mutagenesis; also, a broad range of ribavirin concentration in human serum have been reported during treatment (discussing and references in Ortega-Prieto et al., 2013). Furthermore, there are several reasons to miss a mutagenic activity in vivo with current analytical procedures. Ribavirin produced transient expansions followed by compression of mutant spectrum complexity in model studies with FMDV in cell culture (Ojosnegros et al., 2008; Perales et al., 2011b) (Fig. 9.9). A possible interpretation is that when the mutational load due to ribavirin mutagenesis surpasses some critical value, increasingly defective genomes cease to contribute to progeny, resulting in mutant spectrum compression. Additional variations in FMDV mutant spectrum complexity were observed upon other mutagenic treatments and their interruption (discussed in Ojosnegros et al., 2008).

These model studies render unsurprising that no consistent expansions of HCV mutant spectra have been observed in patients subjected to ribavirin-based treatments or in chronically infected, untreated patients (compare, e.g., Farci et al., 2000; Duffy et al., 2002; Sullivan et al., 2007; Ramachandran et al., 2011; Palmer et al., 2014). Thus, even during ribavirin treatment alteration of mutant spectrum complexity may be missed depending on the time after treatment onset at which the viral sample is obtained. Also, it is necessary to quantify the amount of viral RNA to ensure that the sequence analyses either by standard molecular cloning-Sanger sequencing or deep sequencing provide a faithful representation of the biological sample (see Section 3.6.4 in Chapter 3). In our view, it is unlikely that a mutagenic activity readily observed in cell culture may be totally absent and bear no relationship with the activity of ribavirin in vivo, even though other mechanisms of ribavirin action may also play a role in its overall antiviral activity.

A mutagenic activity of ribavirin has been documented in cell culture with HCV and subgenomic replicons (Contreras et al., 2002; Zhou et al., 2003; Kanda et al., 2004; Ortega-Prieto et al., 2013), albeit with exceptions (Kato et al., 2005; Mori et al., 2011). The main problem to interpret the mechanism of antiHCV activity of ribavirin in vivo is that this antiviral agent can act through several nonexclusive mechanisms, including: (i) immunomodulatory activity with enhancement of the Th1 antiviral response (Hultgren et al., 1998; Ning et al., 1998); (ii) upregulation of expression of genes related to IFN signaling pathways (Zhang et al., 2003; Feld et al., 2007); (iii) depletion of intracellular guanosine-5′-triphosphate (GTP) levels associated with the inhibition of inosine-monophosphate dehydrogenase (IMPDH, the enzyme that
converts inosine-monophosphate into xanthosine-monophosphate in the GTP biosynthesis pathway) by ribavirin-monophosphate (RMP) (Streeter et al., 1973), with a mutagenic effect of reduced inosine triphosphate (ITP) pyrophosphatase activity (which is associated with a common allelic variant in humans) (Nyström et al., 2018); (iv) inhibition of mRNA cap formation (Goswami et al., 1979); (v) inhibition of viral polymerases, independent of a mutagenic activity (Eriksson et al., 1977; Wray et al., 1985; Toltzis et al., 1988; Fernandez-Larsson et al., 1989; Maag et al., 2001; Bougie and Bisaillon, 2003); (vi) lethal mutagenesis, as evidenced with several RNA viruses (some of the studies are listed in Table 9.1), but not with other viruses (Leysen et al., 2005, 2006; Kim and Lee, 2013). As general reviews of the antiviral properties of ribavirin, see (Snell, 2001; Graci and Cameron, 2002; Parker, 2005; Beaucourt and Vignuzzi, 2014).

It is not easy to separate an inhibitory from a mutagenic activity exerted by mutagenic base or nucleoside analogs and their intracellular derivatives. Inhibition may be a consequence of mutagenesis or inhibition and mutagenesis may have two totally separate modes of action. In the case of the antiviral activity of FU against FMDV, it was possible to show inhibition of the uridylylation of primer protein VPg (the initial step of picornavirus RNA synthesis) by 5-fluorouridine-triphosphate (FUTP), in addition to a mutagenic activity of FUTP during RNA elongation (Agudo et al., 2008). In the case of ribavirin, the situation is more complex, and participation of several of the six mechanisms listed in the previous paragraph in its anti-HCV activity, including human alleles that can potentiate mutagenesis (Nyström et al., 2018), should be considered. In particular, it would be interesting to reexamine the evidence for inhibition of viral polymerases to ascertain that the inhibition is independent of mutagenic activity. An interesting possibility is that inadvertently lethal mutagenesis might have been the mode of action of broad-spectrum antiviral agents used for decades, and traditionally considered standard nonmutagenic inhibitors.

9.5.1 Favipiravir as antiviral inhibitor and mutagen

Favipiravir was discovered by Y. Furuta and colleagues as an effective antiviral agent against IV (Furuta et al., 2002, 2017). It has proven effective against a broad range of RNA viruses, with documented inhibitory, RNA chain termination and mutagenic activities in cell culture and in vivo [several studies are included in Table 9.1, and have been reviewed (Perales et al., 2019). A significant result was reported by X. de Lamballe and colleagues who showed that in experimental infections of macaques with Ebola virus, a protective activity of favipiravir was conferred by drug doses that evoked virus mutagenesis (Guedj et al., 2018).

The ongoing studies with favipiravir, and many others on ribavirin that can now be considered a classic in antiviral designs have elevated lethal mutagenesis to the rank of a realistic antiviral strategy. The concept offers promise for additional mutagenic nucleotide (perhaps new drugs designed to modify polymerase fidelity without themselves being nucleotide analogs) for emerging viral infections (that we know are going to happen despite our incapacity to anticipate which, how, and when) and established infections for which new treatment options may become a necessity. As with any type of antiviral agent, however, preclinical and clinical assays will precede their licensing for human use [discussed in (Perales et al., 2019)]. The challenge remains for the lethal mutagens-mediated selection of mutant viruses that display resistance either to the mutagenic activity itself or to the consequences of mutagenesis.
9.6 Virus resistance to mutagenic agents: multiple mechanisms and evidence of abortive escape pathways

It took more than 1 decade of use of ribavirin to obtain the first resistant mutants using Sindbis virus and mycophenolic acid (a nonmutagenic inhibitor of IMPDH); the selected mycophenolic acid-resistant mutants displayed cross-resistance to ribavirin (Scheidel et al., 1987; Scheidel and Stollar, 1991). A decade later the first ribavirin-resistant mutants of poliovirus selected in the laboratory (Pfeiffer and Kirkegaard, 2003), and of HCV from patients under ribavirin monotherapy were described (Young et al., 2003). Subsequent work has characterized viral mutants resistant to mutagenic agents, particularly ribavirin, FU, and 5-AZA-C (Pfeiffer and Kirkegaard, 2005b; Sierra et al., 2007; Arias et al., 2008; Agudo et al., 2010; Levi et al., 2010; Arribas et al., 2011; Feigelstock et al., 2011; Domingo-Calap et al., 2012; Sadeghipour et al., 2013; Zeng et al., 2013, 2014; among other studies). The major overall conclusion of these investigations is that viruses can develop resistance to mutagenic nucleotide analogs as they do to nonmutagenic inhibitors.

Several mechanisms of resistance to mutagenic nucleotide analogs have been described, and the major ones are listed in Box 9.3. They can be broadly divided into two main categories: modifications of the viral polymerase and modification of other proteins. The first substitution to be described that conferred ribavirin resistance was G64S in the PV polymerase (3D) that resulted in an increase of polymerase template-copying fidelity. Studies with PV harboring this mutation have been instrumental in showing the relevance of mutant spectrum complexity in virus adaptability (Pfeiffer and Kirkegaard, 2005a; Vignuzzi et al., 2006) (see Section 2.6 in Chapter 2). These and other studies have established the important concept that to maintain adequate fitness and a good survival probability, a virus population must keep its

---

### BOX 9.3

**Main molecular mechanisms of resistance to mutagenic nucleotide analogs**

- **Amino acid substitutions in the viral polymerase:**
  - Substitutions that increase the general copying fidelity of the enzyme.
  - Substitutions that specifically limit the incorporation of the mutagenic nucleotide.
  - Substitutions that modulate the relative incorporation of the standard nucleotides.

- **Amino acid substitutions in other viral proteins:**
  - Substitutions in nonstructural viral proteins that participate in viral replication or modify polymerase fidelity or modulation of nucleotide incorporation.

- **Combinations of some of these mechanisms.**

- **Fitness-enhancing mutations (unrelated to resistance per se) can contribute to the expression and stability of the resistance trait.**

(Most virological studies have involved base or nucleoside analogs rather than nucleoside-triphosphates. It is assumed that at least for the mechanisms described to date, base and nucleosides are converted into the nucleoside-triphosphate derivatives which are responsible for the mutagenic activity. See text for references).
genome heterogeneity within a suitable range: too low a diversity impairs adaptability, and too high a diversity may approach the population to an extinction threshold (Smith et al., 2013; Smith and Denison, 2013; Zeng et al., 2014). Several studies have demonstrated an attenuation phenotype associated with low- or high-fidelity viral mutants (Borderia et al., 2016; Rai et al., 2017). In a clinical setting, maintaining mutant spectra of viruses within a suitable amplitude range is one of the predictors of viral survival and progression toward disease (Section 8.8 in Chapter 8).

9.6.1 Unpredictable effects of some polymerase substitutions

The same amino acid substitution in the polymerase of related viruses may have a different phenotypic effect. The ribavirin resistance, fidelity-enhancing PV substitution G64S in 3D was obtained independently in two different laboratories (Pfeiffer and Kirkegaard, 2003; Castro et al., 2005). This suggested that PV may have a very restricted number of mutations to attain ribavirin resistance, despite ample evidence that viruses generally display alternative mutational pathways toward resistance to nonmutagenic inhibitors (Section 8.4.5 in Chapter 8), and more generally, multiple pathways for fitness gain (Escarmís et al., 1999; Nguyen et al., 2012; Cabanillas et al., 2013; Arenas et al., 2016). When FMDV whose polymerase is closely related to that of PV (Ferrer-Orta et al., 2004) was passaged in the presence of ribavirin, replacement G62S (the one equivalent to G64S in PV) was not selected. Instead, 3D substitution M296I became dominant and conferred ribavirin resistance (Sierra et al., 2007). A mutant FMDV encoding G62S in 3D that was constructed by site-directed mutagenesis displayed a strong selective disadvantage relative to the standard virus, that was partially compensated by the presence of M296I. The mutant reverted upon passage in cell culture while FMDV with substitution M296I in 3D was stable (Ferrer-Orta et al., 2010). The comparison of the enzymological properties of the FMDV polymerase (3D) with either G62S, M296I, or both indicated that G62S impairs RNA binding, RNA polymerization, and the incorporation of RMP into RNA. Therefore, despite G62S being of potential benefit for the replication of FMDV in the presence of ribavirin, its selection would be abortive. Despite the sites of substitution G62S and M296I being separated by 13.1 Å, a network of interactions allowed a cross-influence between the two sites, with an effect on the catalytic domain of the enzyme (Ferrer-Orta et al., 2010). Still, with FMDV, the same amino acid substitutions in 3D can have opposite effects on template copying fidelity depending on the viral serotype (sequence context) (Li et al., 2018). Some polymerase substitutions may evoke resistance to multiple mutagenic nucleotides, such as cross-resistance to ribavirin and the nucleoside derivative of T-1106 of St. Louis encephalitis virus mutants (Griesemer et al., 2017). Thus, due to distance effects and the subtle, sequence-dependent network connections among residues within the polymerase molecule, the same amino acid replacement may have disparate and unpredictable effects on the behavior of closely related polymerases.

9.6.2 Polymerase fidelity and modulation of nucleotide incorporation

Substitution M296I in 3D of FMDV offers an example of mutagen resistance that limited the incorporation of RMP in the viral RNA without significant alteration of the general template-copying fidelity of the enzyme (Sierra et al., 2007; Arias et al., 2008) (Box 9.3). Fitness of the mutant FMDV relative to the standard virus was 3.8 in the presence of 800 µM ribavirin, and 0.5 in the absence of ribavirin [these values represent a selective strength of 7.6 for
substitution M296I (f Ribavirin/f - Ribavirin), calculated as described in Section 8.4.4 of Chapter 8).

The selective strength conferred by substitution M296I was not sufficient to maintain this substitution as the only one in 3D for the virus to respond to higher ribavirin concentrations. Passage of the 3D M296I mutant virus in the presence of larger concentrations of ribavirin, resulted in the selection of two additional substitutions, P44S and P169S, to yield a virus with the triple substitution P44S, P169S, and M296I in 3D; this triple mutant was termed SSI (Agudo et al., 2010). The selective strength of the triple mutant measured in the presence of 800 μM ribavirin was 18.3, 2.4-fold higher than the selective strength conferred by M296I alone. Significantly, the most salient biochemical feature displayed by the mutant polymerase was that P44S restricted the incorporation of RMP more strongly opposite C than opposite U, as determined in several in vitro incorporation assays. As a consequence, during replication in the presence of ribavirin, mutant SSI could maintain a balance of the different transition types [measured as the ratio of (G → A) + (C → U) to (A → G) + (U → C) mutations] typical of the standard virus when replicating in the absence of mutagens (Agudo et al., 2010) (see Fig. 9.8 for the ribavirin-mediated mutational pathways). The modulation mechanism associated with 3D substitution P44S in FMDV is one of the mutagen resistance mechanisms listed in Box 9.3. Modulation of transition types allows the virus to maintain its typical mutant spectrum complexity with its corresponding adaptability. Interestingly, substitution P169S contributed a selective advantage only in the presence of very high (5000 μM) ribavirin concentrations, once the transition-modulating phenotype through P44S had already been acquired. Box 9.3 also lists as mutations contributing to mutagen escape those that increase fitness without being bona fide resistance mutations. Comparison of the fitness-enhancing mutations described for antiviral resistance (Chapter 8) and the effect of P169S in 3D of FMDV suggests that such mutations can be divided into two classes: those that increase fitness generally and those that do so only in the presence of mutagen and even in the presence of some range of mutagen concentrations (Agudo et al., 2010).

The analyses of mutant spectra produced by FMDV with the standard and SSI 3D in the absence and presence of ribavirin suggest that a bias in favor of G → A and C → U may be detrimental to the virus presumably because it may modify RNA and protein composition, and probably also increase the frequency of defective genomes. The latter was suggested by the presence of a stop codon in one of the clones of the mutagenized standard virus population (Agudo et al., 2010).

The three-dimensional structures of the ribavirin-resistant polymerases revealed alterations in the N-terminal region of 3D (Agudo et al., 2010), affecting sites that belong to a nuclear localization signal (NLS) present in FMDV 3D (Sanchez-Aparicio et al., 2013). Amino acid substitutions within the NLS that diminished the transport to the nucleus of 3D and 3D3C (a functional precursor intermediate of 3D and the protease 3C) also modified the template binding and nucleotide recognition properties of 3D (Ferrer-Orta et al., 2015; de la Higuera et al., 2018). Interestingly, some replacements within the NLS increased the incorporation of RMP relative to standard substrates, suggesting that structural alterations in viral polymerases may enhance the vulnerability of viruses to nucleotide analogs. The results on the effect of amino acid substitutions within the NLS of FMDV 3D emphasize the multifunctional nature of this viral polymerase, in line with the recognized multifunctionality of many viral proteins, a feature that increases vulnerability to lethal mutagenesis. Despite uncertainties repeatedly exposed in this book (dependence of enzyme behavior on the protein and template sequence context, behavior modifications due
to introduction of additional amino acid substitutions, etc.) it can be envisaged that through structure-based designs, new drugs could be found that are tailored to viral polymerases to enhance the incorporation of mutagenic nucleotides; they could be added to existing nucleotide analogs to formulate new antiviral combinations.

The comparison of the several amino acid and groups of amino acid substitutions that in 3D of FMDV can be involved in ribavirin resistance (Sierra et al., 2007; Agudo et al., 2010; Zeng et al., 2014; Ferrer-Orta et al., 2015) suggests that there are multiple, in some cases even independent, evolutionary pathways for a virus to achieve resistance to mutagenic agents, as there are multiple pathways toward resistance to standard, nonmutagenic inhibitors. In the case of PV, different ribavirin resistance substitutions would be expected if independent viral lineages were subjected to a range of ribavirin concentrations. Modulation of nucleotide incorporation is also a mechanism of FMDV resistance to FU through a single polymerase substitution that prevents the excess of A to G and U to C transitions induced by this analog (de la Higuera et al., 2017). An added advantage of the selection of mutants with altered mutational spectrum is that they may lead to virus attenuation in different hosts (Warmbrod et al., 2019). Thus, there is ample evidence with several viral systems that polymerase substitutions can modulate nucleotide incorporation, and that modulation per se is a mechanism of resistance to lethal mutagenesis.

The viral polymerases are not the only determinants of template-copying fidelity. The viral replicative machineries consist of a complex of several viral and host proteins, and it has been shown that proteins other than the polymerase can also contribute to polymerase fidelity and resistance to mutagenic agents (Box 9.3). When the triple SSI ribavirin-resistant mutant of FMDV (Agudo et al., 2010) was further passaged in the presence of high ribavirin concentrations, a population that included replacement I248T in nonstructural protein 2C was selected (Agudo et al., 2016). The possibility that the read-through protein of bacteriophage Qb may contribute to 5-AZA-C resistance was suggested by a study of E. Lázaro and colleagues (Arribas et al., 2011), although limited amino acid substitutions in the viral replicase can confer resistance (Cabanillas et al., 2014). The small, nonenzymatic coronavirus nonstructural protein 10 is involved in maintaining the replication fidelity of the virus (Smith et al., 2015). Two substitutions in protein NS5A of an HCV replicon conferred low-level resistance to ribavirin (Pfeiffer and Kirkegaard, 2005b). In the case of the DNA bacteriophage φX174 that does not encode its own polymerase, FU resistance was achieved through substitutions in the virus-coded lysis protein (Pereira-Gomez and Sanjuan, 2014). It was proposed that delayed cell lysis, increase in the amount of progeny virus per cell, and limitation of the number of infectious cycles reduced the chances of mutagenesis (also discussed in Section 8.5 of Chapter 8 with regard to general molecular mechanisms of antiviral resistance). Therefore, current evidence anticipates multiple adaptive mechanisms of virus resistance to mutagenic nucleotides, not necessarily confined to the polymerase as documented for standard inhibitors. There is, however, an interesting possibility of an initial advantage of mutagenic agents over standard inhibitors to impede selection of resistant mutants. Before justifying this suggestion, current therapeutic alternatives based on lethal mutagenesis are discussed.

9.7 Virus extinction as the outcome of replacement of virus subpopulations: tempo and mode of mutation acquisition

Some general considerations derived from the observations described in previous sections are worth commenting. The extinction of a virus is not only a consequence of the reduction of viral
load (with insufficient $R_0$ value to ensure cell-to-cell transmission to sustain the infection; see Section 7.2 in Chapter 7 for the concept of $R_0$), or of a simple movement in sequence space, or even of an increase of mutational load in replicating genomes. It is the result of a combination of several influences under specific circumstances of the kinetics of accumulation of mutations in viral genomes. We consider these points in turn.

Studies by N. Pariente, C. Perales, and colleagues showed that a given reduction in viral load achieved through mutagenesis was sufficient to drive FMDV toward extinction, but that when the same reduction was achieved through inhibition, it did not lead to virus extinction (Pariente et al., 2001, 2003; 2005; Perales et al., 2011a). The main difference is that mutagenesis is a dynamic process of genome variation and reduction of viral load, while inhibition is basically a static process regarding the incorporation of mutations. Only when a decrease in viral load has already taken place, the virus becomes more vulnerable to mutagenesis (Sierra et al., 2000).

Movements in sequence space are the norm during virus replication and evolution, independently of being subjected to increased mutagenesis or not. An A, U-rich genome subpopulation that became dominant upon passage of FMDV in the presence of ribavirin also existed in the standard viral population, albeit at a lower level (Perales et al., 2011b). That is, the main effect of ribavirin was to shift the dominant part of the mutant spectrum into an A, U-rich region. This shift may increase the presence of defective genomes, including defectors that interfere with replication of the standard virus (Section 9.3.1). We encounter here again one of the main departures introduced by quasispecies in the understanding of virus evolution: replacement of some genome subpopulations by others. In the case of extinction, the movement consists of the replacement of standard subpopulations by others lying in unfavorable portions of sequence space. Expressed in another manner: mutagenesis forces an uncontrolled, not a fitness gradient-mediated, relocalization in sequence space.

The mutational load, calculated as the number of mutations incorporated in an individual genome is not by itself a predictor of survival or extinction. It depends on the location of the mutations. Accumulation of mutations may reduce fitness and robustness to the effect of additional mutations (Section 6.7.1 in Chapter 6) but still allow replicative competence. An FMDV clone subjected to multiple plaque-to-plaque transfers accumulates mutations at a rate of $0.1-0.25$ mutations per passage, which implies that viable FMDV genomes can accumulate a number of mutations equivalent to a mutation frequency of $10^{-2}$ substitutions per nucleotide (Escarmís et al., 2008). A 10-fold lower mutation frequency is sufficient to extinguish the same viral clone upon passage in the presence of a mutagenic agent. The tempo and mode of accumulation of mutations is the determinant factor. E. Lázaro and colleagues showed that 5-AZA-C enhanced Qβ replication during plaque development, but drove the virus to extinction during growth in the liquid culture medium unless a mutagen-resistant Qβ was selected (Cases-Gonzalez et al., 2008; Arribas et al., 2011). The experimental design in the plaque transfers is such that at each transfer a viral particle capable of developing a visible plaque on the cell monolayer is rescued no matter how many companions are left behind (extinguished). The applied selection is powerful. In contrast, during mutagenesis without intervening plaque isolations, no means to recover viable minority survivors are included in the design: if a rare potential survivor with a cluster of mutations arises transiently, it will be suppressed by the surrounding mutant spectrum or will perish due to the next rounds of mutagenesis. Thus, even if beneficial mutations are more likely to arise in low-fitness genomes, their contribution to survival is minimal under a continuing mutagenic environment.

A critical point for prediction of virus extinction is how close to an error (or extinction)
threshold virus replication takes place. The evidence is that DNA genomes whose replication is catalyzed by a high-fidelity DNA polymerase may resist transient increases of mutation rate and even benefit from them (Cupples and Miller, 1989; Solé and Deisboeck, 2004; Springman et al., 2010). Thus, viral extinction by enhanced mutagenesis is conditioned by several factors related mainly to basal replicative parameters of the virus and the kinetics of mutagenesis.

### 9.8 The interplay between inhibitors and mutagenic agents in viral populations: sequential versus combination treatments

As a test of the paradigm of the general advantage of combination therapies over monotherapy, initial experiments were designed to study the efficacy of a combination of a mutagenic agent and an antiviral inhibitor. The results documented that extinction of high-fitness FMDV or HIV-1 could be achieved by a combination of a mutagenic agent and a nonmutagenic inhibitor, but not with the mutagenic agent alone (Pariente et al., 2001, 2005; Tapia et al., 2005). Despite being an expected result, additional experiments pursued by C. Perales with FMDV demonstrated that the response of the virus to the combined action of an inhibitor and a mutagenic agent is a bit more complex than initially thought. The production of infectivity and viral RNA was measured in the course of viral passages in the presence of the inhibitor guanidinium chloride alone, or ribavirin alone, or a combination of guanidinium chloride and ribavirin, or with an initial passage in the presence of guanidinium chloride, followed by passages in the presence of ribavirin alone (Fig. 9.10). The results of quantification of FMDV progeny and a sensitive RT-PCR test of virus extinction, documented that the design consisting of administering guanidine alone first, followed by additional passages in the presence of ribavirin alone was the most effective to reduce progeny production and to drive the virus toward extinction (Fig. 9.10B–E) (Perales et al., 2009b). S. Manrubia developed a theoretical model whose main parameters were the concentration of standard and defective viruses sensitive and resistant to the inhibitor, the viral mutation rate, the rate of generation of inhibitor-resistant mutants, the number of standard and defective progeny genomes, and the number of infected cells and of infectious cycles per cell. The model (described in Perales et al., 2009b; Iranzo et al., 2011) explained the advantage of the sequential inhibitor-mutagen administration protocol over the corresponding combination in terms of replicative parameters and intensity of mutagenesis. When an inhibitor and a mutagen are present together during viral replication, their joint influence on the viral RNA may jeopardize virus extinction (possible mechanisms are summarized in Box 9.4). Notably, the presence of the mutagen may transiently increase the frequency of inhibitor-resistant mutants, and therefore, favoring virus escape and treatment failure. A second mechanism by which the simultaneous presence of an inhibitor and mutagen can impede virus extinction is that in the presence of the inhibitor, the RNA defectors that are generated by mutagenesis of the viral RNA cannot interfere with viral replication. The reason is that defector replication is needed for lethal defection (Section 9.3.1), presumably because replication increases the amount of RNA that encodes trans-acting substituted proteins that are detrimental to the virus life cycle, and responsible for lethal defection (Grande-Pérez et al., 2005b).

The advantage of sequential inhibitor-mutagen administration has also been evidenced with LCMV, taking advantage of the double inhibitor and mutagenic character of ribavirin, that depends on its concentration (Moreno et al., 2012). For each virus-host system, it will be necessary to carry out experiments to delimit the range of inhibitor and mutagen concentrations at which the sequential treatment is advantageous. The translation into clinical practice is of interest,
FIGURE 9.10 Alternative antiviral designs using an inhibitor and a mutagenic agent. This model study was carried out with FMDV replicating in BHK-21 cells. The inhibitor used was guanidine hydrochloride (GU), and the mutagen was ribavirin (R). (A) The four types of serial passages (p indicates passage number) are, from top to bottom: passages in the presence of guanidine alone (yellow diamond); passages in the presence of ribavirin (R) alone (red triangle); passages in the presence of a mixture of GU and R (denoted as [GU + R]; red star; passage number is in quotes because the first passage with the mixture of GU and R was considered equivalent to the second passage in the presence of a single drug); finally, a first passage in the presence of GU, followed by four passages in the presence of R (blue circle). (B), (C), (D) Virus titer and viral RNA level in the course of six passages in the presence of 5 mM R and 16, 18, 20 mM GU in (B), (C), (D), respectively, with passage regimen code indicated in the box. Note that the highest reductions of FMDV progeny production are achieved using the sequential GU-R protocol (blue circle) and that infectivity and viral RNA are lost earlier at the highest GU concentration tested. (E) A highly sensitive RT-PCR amplification used as diagnostic of viral extinction confirmed the advantage of the sequential GU-ribavirin treatment. Symbols are as in (A). Figure reproduced from Perales, C., Agudo, R., Tejero, H., Manrubia, S.C., Domingo, E., 2009b. Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections. PLoS Pathog. 5, e1000658 where additional experimental details can be found.
but it will have the added complications derived from target compartmentalization and uneven inhibitor and mutagen concentrations in different compartments (Steinmeyer and Wilke, 2009). The model of S. Manrubia and J. Iranzo also predicts that when therapy is based on the use of either two mutagenic agents or two inhibitors, a combination treatment is always preferred over the sequential administration. Only a few studies have investigated the consequences of using two mutagens together, with or without inhibitors (Perales et al., 2009a; Dapp et al., 2012). The availability of two or more virus-specific mutagen agents of different mutational preferences has the advantage that they will target different regions of sequence space (related to network connections discussed in Chapter 10), although the resulting mutational patterns may be difficult to interpret (Dapp et al., 2012). Also, a mutagen may extinguish a virus that has acquired resistance to another mutagen as in the extinction of a ribavirin-resistant FMDV mutant by FU (Perales et al., 2009a). According to the model, the worst option is to administer first a mutagen and then an inhibitor. Unless the mutagen achieves extreme reductions of viral load, it may generate an expanded mutant spectrum from which inhibitor-resistant mutants may be selected (Iranzo et al., 2011; Perales et al., 2012).

### BOX 9.4

**Interactions between inhibitors and mutagenic nucleotides that can affect the efficacy of combination treatments**

- A mutagen can increase the frequency of inhibitor-resistant mutants.
- An inhibitor can prevent replication of interfering mutants that contribute to lethal defection.
- The mutant spectrum can suppress inhibitor-resistant mutants that affect a trans-complementable protein.
- A mutagenized mutant spectrum can suppress high-fitness genomes.

See text for justification and references.

### 9.9 Prospects for a clinical application of lethal mutagenesis

Lethal mutagenesis constitutes an example of how a fundamental theoretical concept initially unrelated to virology can unfold into a potential application in the form of antiviral designs. This transition is exemplified by M. Eigen, who established the basis of quasispecies theory (Eigen, 1971) and wrote a comment of a paper on virus extinction by mutagenic nucleotides, 30 years later (Eigen, 2002). Can you imagine a grant application to work on quasispecies with the aim of controlling viral infections? Some readers will probably object immediately: nothing has been achieved yet with lethal mutagenesis at the clinical level. True, unless ribavirin has been clearing (or helped the immune system to clear) HCV, with the participation of mutagenesis (see Section 9.5). To be able to talk about the prospect of an application is sufficient to make the point about the relevance of basic research, and it is the prospect that we address here.

Box 9.5 lists advantages and limitations of lethal mutagenesis treatments as compared with standard, nonmutagenic inhibitors. Quantifications of mutagen-escape mutant frequencies have not been performed. The derivation of
some of the mutants that have been studied (Section 9.6) required a gradual increase of mutagen concentration in the course of selective passages. The difficulty in isolating mutants from a mutagen-treated viral population may stem from the suppressive environment created by the mutagenesis itself that may preclude or delay dominance of the resistant mutant.

The possibility of sequential inhibitor-mutagen treatments (Section 9.8) is clinically relevant because such designs may diminish the severity of side effects by avoiding the simultaneous presence of two drugs in treated patients. Shorter treatment duration of sequential treatments is also a possibility.

Some natural cellular mechanisms of defense against genetic parasites are based on producing an excess of mutations in the invader. In Chapter 2 (Section 2.7), APOBEC (apolipoprotein B mRNA editing complex) and ADAR (adenosine deaminase acting on double-stranded RNA) were discussed. They exert nucleic acid editing functions used by the cell that can be recruited as antiviral responses (Harris and Dudley, 2015; Venkatesan et al., 2018). Editing is part of the replication cycle of several viruses. It has been suggested that Paramyxovirinae might have evolved to possess a genome of polyhexameric length (known as the “rule of six”) to avoid uncontrolled editing and error catastrophe of the virus (Kolakofsky et al., 2005). There are additional mutagenic-like activities that mimic lethal mutagenesis. One of them is termed RIP (repeat-induced point mutations) that operates in some filamentous fungi to mutate genetic intruders, including transposable elements (Galagan and Selker, 2004; Clutterbuck, 2011; Braga et al., 2014; Amselem et al., 2015; Van de Wouw et al., 2019). Some experts regard as highly positive that an intended medical intervention resembles a natural process.

---

**BOX 9.5**

**Advantages and limitations of antiviral treatments based on lethal mutagenesis**

**Advantages**

- A possible high barrier to resistance.
- Its mechanism of action favors the suppression of possible resistant variants by the mutagenized mutant spectrum within infected cells.
- Lethal mutagenesis may be included in sequential or combination designs with other classes of antiviral agents.
- Natural mechanisms of resistance to genetic parasites include lethal mutagenesis-like strategies: APOBEC, ADAR, RIP, etc.

**Limitations**

- The mutagenic activity of the agents must be virus specific. It cannot mutagenize cellular nucleic acids.
- Possible off-target effects are still poorly understood.
- The number of available antiviral mutagenic agents is restricted.
- Additional experiments with animal models and preclinical and clinical trials are needed prior to possible therapy implementation.
- Resistance of expert panels to encourage the exploration of unconventional antiviral approaches both for scientific and commercial reasons.
Box 9.5 also lists several limitations, some of which are obvious (need of specificity to mutagenize viral but not cellular nucleic acids, lack of information on off-target effects, and a necessity to explore treatment efficacy in vivo). It is likely that the number of virus-specific mutagenic agents will increase in the coming decades. If their efficacy in vivo can be properly documented, expert panels may moderate their attitude toward these and other new antiviral approaches [discussion of the licensing issue in (Perales et al., 2019)].

9.10 Some atypical proposals

Decisions on the suitability of new treatments are mainly based on the three basic parameters CC\textsubscript{50} (as a measure of toxicity), IC\textsubscript{50} (as a measure of inhibitory potential), and the therapeutic index that they yield (TI = CC\textsubscript{50}/IC\textsubscript{50}) (explained in Section 8.4.3 of Chapter 8). There is an additional parameter that should also be considered: the spectrum of antiviral activity, regarding the number of unrelated viral pathogens that are effectively inhibited by the treatment. Although evidence is still lacking, the possibility that broad-spectrum in the above sense may predict a capacity to inhibit broad repertoires of quasispecies swarms is appealing. The broadness of antiviral efficacy is dependent on the mechanism of antiviral activity. In this and the preceding chapters, we have described two classes of broad-spectrum antiviral inhibitors: those that stimulate the innate immune response (notably inhibitors of pyrimidine biosynthesis) and mutagenic nucleotide analogs (notably ribavirin and favipiravir as the most relevant examples, likely to be followed by additional ones). Thus, it would be interesting to investigate the joint use of these two classes of compounds (stimulators of immune responses and lethal mutagens) in sequential or combination protocols of the type described in Section 9.8.

Drug repositioning may offer additional possibilities. F. Sobrino and colleagues demonstrated that valproic acid (2-propylpentanoic acid, VPA) displays a broad antiviral activity against many enveloped viruses (Martin-Acebes et al., 2011; Vazquez-Calvo et al., 2013). VPA is used to treat epilepsy and bipolar mania, among other disorders. It is listed among the essential medicines by the World Health Organization. Despite its antiviral potency being modest, its inclusion as part of combined therapies should also be considered in view of its broad-spectrum of activity. Triple, broad-spectrum drug combinations appear as an attractive possibility provided antagonistic interactions are avoided, and the side effects are tolerable.

There is a long way to go before lethal mutagenesis or other new designs based on the concepts listed in Box 9.1 can be applied to the treatment of viral disease. However, the hope is that the experience gained mainly with HIV-1 but also with other error-prone viruses will favor explorations that regard the adaptive potential of viruses as the major challenge to be confronted.

9.11 Overview and concluding remarks

It is uncertain whether the possibilities presented here as new trends in antiviral strategies will satisfy the demands of new paradigms to approach infectious disease (emphasized in the opening paragraphs of this chapter), or it will be necessary to wait for more innovative advance. The available possibilities have as a common trend that they respond to the quasispecies challenge, and fulfill requirements expressed repeatedly in this book: viral populations to be controlled should be denied any opportunity to replicate, because replication entails the exploration of sequence space, which is a condition for adaptation. Viruses have to be hit hard and as soon as possible both at the level of individual infections and at the epidemiological level. To the extent
that new treatment designs can fulfill this requirement, they are worth being pursued.

Probably, combinations of broad-spectrum antiviral agents, irrespective of their nature (lethal mutagens, stimulators of the immune response, mixtures of highly neutralizing antibodies, or their combinations) are among the best options presently available. Despite the general preference for combination treatments, once a mutagenic agent enters the antiviral formulations, the possibility of sequential inhibitor-mutagen treatments should be considered. They may be as effective as the corresponding combinations and may alleviate the burden of side effects, one of the problems of current treatments.

Given the challenge of existing viral diseases and the emergent viral diseases unavoidably to come, what should not be done is to minimize the importance of the challenge, and as a consequence, withdraw the focus from the essential issue. Antiviral designs must be planned by counting on quasispecies dynamics. Controversies about which theoretical models best describe extinction of viruses by lethal mutagenesis should be used to clarify antiviral mechanisms and find the adjustments for best efficacy. Controversies should not be presented as evidence against the real nature of dynamic quasispecies. With the application of deep sequencing to viral populations, the challenge has become dramatically evident. New antiviral targets, new drugs (mutagenic and nonmutagenic), and studies with animal models will hopefully contribute to reaching the goal (see Summary Box).

**Summary Box**

- There is a need to develop new antiviral strategies to control viral pathogens characterized by quasispecies dynamics.
- Several new designs have been implemented or are under investigation. They aim at increasing the barrier to resistance or diminishing viral fitness.
- Lethal mutagenesis consists of virus extinction by excess mutations. Experimental evidence suggests that lethal mutagenesis is directly related to the error threshold concept of quasispecies theory.
- Mutagen-resistant viral mutants have been isolated, and their study has been instrumental in documenting the adaptive value conferred by a mutant spectrum of adequate complexity.
- There are several molecular mechanisms of virus resistance to mutagenic agents. One of them is modulation of nucleotide incorporation, selected to counteract the mutational bias evoked by a mutagen while maintaining the level of mutant spectrum diversity.
- Sequential inhibitor-mutagen treatments may have an advantage over the corresponding combination, depending on replicative parameters of the virus to be controlled and the inhibitory and mutagenic intensities.
- New treatments using broad-spectrum mutagenic and nonmutagenic drug combinations offer prospects for the control of error-prone viruses.
References

Agudo, R., Arias, A., Pariente, N., Perales, C., Escarmis, C., et al., 2008. Molecular characterization of a dual inhibitory and mutagenic activity of 5-fluorouridine triphosphate on viral RNA synthesis. Implications for lethal mutagenesis. J. Mol. Biol. 382, 652–666.

Agudo, R., Arias, A., Domingo, E., 2009. 5-Fluorouracil in lethal mutagenesis of foot-and-mouth disease virus. Future Med. Chem. 1, 529–539.

Agudo, R., Ferrer-Orta, C., Arias, A., de la Higuera, I., Grande-Perez, A., et al., 2010. A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape. PLoS Pathog. 6, e1001072.

Agudo, R., de la Higuera, I., Arias, A., Grande-Perez, A., Domingo, E., 2016. Involvement of a joker mutation in a polymerase-independent lethal mutagenesis-escape mechanism. Virology 494, 257–266.

Airaksinen, A., Pariente, N., Menendez-Arias, L., Domingo, E., 2003. Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology 311, 339–349.

Amselem, J., Lebrun, M.H., Quesneville, H., 2015. Whole genome comparative analysis of transposable elements provides new insight into mechanisms of their inactivation in fungal genomes. BMC Genomics 16, 141.

Arenas, M., Lorenzo-Redondo, R., Lopez-Galindez, C., 2016. Influence of mutation and recombination on HIV-1 in vitro fitness recovery. Mol. Phylogenet. Evol. 94, 264–270.

Arias, A., Arnold, J.J., Sierra, M., Smidansky, E.D., Domingo, E., et al., 2008. Determinants of RNA-dependent RNA polymerase (in)fidelity revealed by kinetic analysis of the polymerase encoded by a foot-and-mouth disease virus mutant with reduced sensitivity to ribavirin. J. Virol. 82, 12346–12355.

Arias, A., Isabel de Avila, A., Sanz-Ramos, M., Agudo, R., Escarmis, C., et al., 2013. Molecular dissection of a viral quasispecies under mutagenic treatment: positive correlation between fitness loss and mutational load. J. Gen. Virol. 94, 817–830.

Arias, A., Thorne, L., Goodfellow, I., 2014. Favipiravir elicits antiviral mutagenesis during virus replication in vivo. eLife 3, e03679.

Arribas, M., Cabanillas, L., Lazaro, E., 2011. Identification of mutations conferring 5-azacytidine resistance in bacteriophage Qbeta. Virology 417, 343–352.

Asahina, Y., Izumi, N., Enomoto, N., Uchihara, M., Kurosaki, M., et al., 2005. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J. Hepatol. 43, 623–629.

Baccam, P., Thompson, R.J., Fedrigo, O., Carpenter, S., Cornette, J.L., 2001. PAQ: partition analysis of quasispecies. Bioinformatics 17, 16–22.

Baranovich, T., Wong, S.S., Armstrong, J., Marjuki, H., Webby, R.J., et al., 2013. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J. Virol. 87, 3741–3751.

Bassi, M.R., Navarro Sempere, R., Meyn, P., Polacek, C., Arias, A., 2018. Extinction of Zika virus and Usutu virus by lethal mutagenesis reveals different patterns of sensitivity to three mutagenic drugs. Antimicrob. Agents Chemother. 62, 00380–18.

Beach, L.B., Rawson, J.M., Kim, B., Patterson, S.E., Mansky, L.M., 2014. Novel inhibitors of human immunodeficiency virus type 2 infectivity. J. Gen. Virol. 95, 2778–2783.

Beauchot, S., Vignuzzi, M., 2014. Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance. Curr. Opin. Virol. 8, 10–15.

Bonhoeffer, S., May, R.M., Shaw, G.M., Nowak, M.A., 1997. Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. U.S.A. 94, 6971–6976.

Bonnac, L.F., Mansky, L.M., Patterson, S.E., 2013. Structure-activity relationships and design of viral mutagens and application to lethal mutagenesis. J. Med. Chem. 56, 9403–9414.

Borderia, A.V., Rozen-Gagnon, K., Vignuzzi, M., 2016. Fidelity variants and RNA quasispecies. Curr. Top. Microbiol. Immunol. 392, 303–322.

Borrego, B., de Avila, A.I., Domingo, E., Brun, A., 2019. Lethal mutagenesis of Rift Valley fever virus induced by favipiravir. Antimicrob. Agents Chemother. 63(8), e00669–19.

Bougie, I., Bisaillon, M., 2003. Initial binding of the broad spectrum antiviral nucleoside ribavirin to the hepatitis C virus RNA polymerase. J. Biol. Chem. 278, 52471–52478.

Braga, R.M., Santana, M.F., Veras da Costa, R., Brommonschenkel, S.H., de Araujo, E.F., et al., 2014. Transposable elements belonging to the Tc1-Mariner superfamily are heavily mutated in Colletotrichum graminicola. Mycologia 106, 629–641.

Cabanillas, L., Arribas, M., Lazaro, E., 2013. Evolution at increased error rates leads to coexistence of multiple adaptive pathways in an RNA virus. BMC Evol. Biol. 13, 11.

Cabanillas, L., Sanjuan, R., Lazaro, E., 2014. Changes in protein domains outside the catalytic site of the bacteriophage Qbeta replicase reduce the mutagenic effect of 5-azacytidine. J. Virol. 88, 10480–10487.

Caroline, A.L., Powell, D.S., Bethel, L.M., Oury, T.D., Reed, D.S., et al., 2014. Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever. PLoS Negl. Trop. Dis. 8, e2790.

Casadevall, A., 1996. Crisis in infectious diseases: time for a new paradigm? Clin. Infect. Dis. 23, 790–794.
Casadevall, A., Pirofski, L.A., 2015. The ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases. PLoS Pathog. 11, e1004717.

Cases-Gonzalez, C., Arribas, M., Domingo, E., Lazaro, E., 2008. Beneficial effects of population bottlenecks in an RNA virus evolving at increased error rate. J. Mol. Biol. 384, 1120–1129.

Castro, C., Arnold, J.J., Cameron, C.E., 2005. Incorporation fidelity of the viral RNA-dependent RNA polymerase: a kinetic, thermodynamic and structural perspective. Virus Res. 107, 141–149.

Chatterji, U., Lim, P., Bobardt, M.D., Wieland, S., Cordek, D.G., et al., 2010. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J. Hepatol. 53, 50–56.

Chevaliez, S., Brillet, R., Lazaro, E., Hezode, C., Pawlotsky, J.M., 2007. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J. Virol. 81, 7732–7741.

Chung, D.H., Sun, Y., Parker, W.B., Arterburn, J.B., Bartolucci, A., et al., 2007. Ribavirin reveals a lethal threshold of allowable mutation frequency for Hantaan virus. J. Virol. 81, 11722–11729.

Clutterbuck, A.J., 2011. Genomic evidence of repeat-induced point mutation (RIP) in filamentous ascomycetes. Fungal Genet. Biol. 48, 306–326.

Contreras, A.M., Hiasa, Y., He, W., Terella, A., Schmidt, E.V., et al., 2002. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J. Virol. 76, 8505–8517.

Crotty, S., Maag, D., Arnold, J.J., Zhong, W., Lau, J.Y., et al., 2000. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6, 1375–1379.

Crotty, S., Cameron, C.E., Andino, R., 2001. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. U.S.A. 98, 6895–6900.

Crotty, S., Cameron, C., Andino, R., 2002. Ribavirin’s antiviral mechanism of action: lethal mutagenesis? J. Mol. Med. 80, 86–95.

Cuevas, J.M., Gonzalez-Candelas, F., Moya, A., Sanjuan, R., 2009. Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J. Virol. 83, 5760–5764.

Cummings, K.J., Lee, S.M., West, E.S., Cid-Ruzafa, J., Fein, S.G., et al., 2001. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials. J. Am. Med. Assoc. 285, 193–199.

Cupples, C.G., Miller, J.H., 1989. A set of lacZ mutations in Escherichia coli that allow rapid detection of each of the six base substitutions. Proc. Natl. Acad. Sci. U.S.A. 86, 5345–5349.

Dalgleish, A.G., 2015. Rationale for combining immunotherapy with chemotherapy. Immunotherapy 7, 309–316.

Dapp, M.J., Clouser, C.L., Patterson, S., Mansky, L.M., 2009. 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. J. Virol. 83, 11950–11958.

Dapp, M.J., Holtz, C.M., Mansky, L.M., 2012. Concomitant lethal mutagenesis of human immunodeficiency virus type 1. J. Mol. Biol. 419, 158–170.

Dapp, M.J., Patterson, S.E., Mansky, L.M., 2013. Back to the future: revisiting HIV-1 lethal mutagenesis. Trends Microbiol. 21, 56–62.

Dapp, M.J., Bonnac, L., Patterson, S.E., Mansky, L.M., 2014. Discovery of novel ribonucleoside analogs with activity against human immunodeficiency virus type 1. J. Virol. 88, 354–363.

Day, C.W., Sme, D.F., Julander, J.G., Yamshchikov, V.F., Sidwell, R.W., et al., 2005. Error-prone replication of West Nile virus caused by ribavirin. Antiviral Res 67, 38–45.

De Avila, A.L., Gallego, I., Soria, M.E., Gregori, J., Quer, J., Esteban, J.I., Rice, C.M., Domingo, E., Perales, C., 2016. Lethal mutagenesis of hepatitis C virus induced by favipiravir. PLoS One 11, e0164691.

De Avila, A.L., Moreno, E., Perales, C., Domingo, E., 2017. Favipiravir can evoke lethal mutagenesis and extinction of foot-and-mouth disease virus. Virus Res. 233, 105–112.

De Crignis, E., Mahmoudi, T., 2014. HIV eradication: combinatorial approaches to activate latent viruses. Viruses 6, 4581–4608.

De la Higuera, I., Ferrer-Orta, C., de Avila, A.L., Perales, C., Sierra, M., et al., 2017. Molecular and functional bases of selection against a mutation bias in an RNA virus. Genome Biol. Evol. 9, 1212–1228.

De la Higuera, I., Ferrer-Orta, C., Moreno, E., de Avila, A.L., Soria, M.E., et al., 2018. Contribution of a multifunctional polymerase region of foot-and-mouth disease virus to lethal mutagenesis. J. Virol. 92, e01119–18.

de Wilde, A.H., Pham, U., Posthuma, C.C., Snijder, E.J., 2018. Cyclophilins and cyclophilin inhibitors in nidovirus replication. Virology 522, 46–55.

Delang, L., Vliegen, I., Froeyen, M., Neyts, J., 2011. Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication. Antimicrob. Agents Chemother. 55, 4103–4113.

Di Biscaglia, A.M., Thompson, J., Smith-Wilkaitis, N., Brunt, E.M., Bacon, B.R., 2001. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of non-responders to interferon. Hepatology 33, 704–707.

Diaz-Martinez, L., Brichette-Mieg, I., Pineno-Ramos, A., Dominguez-Huerta, G., Grande-Perez, A., 2018. Lethal mutagenesis of an RNA plant virus via lethal defection. Sci. Rep. 8, 1444.
Dietz, J., Schelhorn, S.E., Fitting, D., Mihm, U., Susser, S., et al., 2013. Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. J. Virol. 87, 6172–6181.

Dixit, N.M., Layden-Almer, J.E., Layden, T.J., Perelson, A.S., 2004. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432, 922–924.

Domingo, E., 1989. RNA virus evolution and the control of viral disease. Prog. Drug Res. 33, 93–133.

Domingo, E., Holland, J.J., 1992. Complications of RNA heterogeneity for the engineering of virus vaccines and antiviral agents. Genet. Eng. 14, 13–31.

Domingo, E., Flavell, R.A., Weissmann, C., 1976. In vitro site-directed mutagenesis: generation and properties of an infectious extracistronic mutant of bacteriophage Qβ. Gene 1, 3–25.

Domingo, E., Grande-Perez, A., Martin, V., 2008. Future prospects for the treatment of rapidly evolving viral pathogens: insights from evolutionary biology. Expert Opin. Biol. Ther. 8, 1455–1460.

Domingo, E., Sheldon, J., Perales, C., 2012. Viral quasispecies evolution. Microbiol. Mol. Biol. Rev. 76, 159–216.

Domingo-Calap, P., Pereira-Gomez, M., Sanjuan, R., 2012. Nucleoside analogue mutagenesis of a single-stranded DNA virus: evolution and resistance. J. Virol. 86, 9640–9646.

Duffy, M., Salemi, M., Sheehy, N., Vandamme, A.M., Hegarty, J., et al., 2002. Comparative rates of nucleotide sequence variation in the hypervariable region of E1/E2 and the NS5b region of hepatitis C virus in patients with a spectrum of liver disease resulting from a common source of infection. Virolology 301, 354–364.

Eggers, H.J., 1976. Successful treatment of enterovirus-infected mice by 2-(alpha-hydroxybenzyl)-benzimidazole and guanidine. J. Exp. Med. 143, 1367–1381.

Eggers, H.J., Tamm, I., 1963. Synergistic effect of 2-(alpha-hydroxybenzyl)-benzimidazole and guanidine on picornavirus reproduction. Nature 199, 513–514.

Eigen, M., 1971. Self-organization of matter and the evolution of biological macromolecules. Naturwissenschaften 58, 465–523.

Eigen, M., 2002. Error catastrophe and antiviral strategy. Proc. Natl. Acad. Sci. U.S.A. 99, 13374–13376.

Eigen, M., Schuster, P., 1979. The Hypercycle. A Principle of Natural Self-Organization. Springer, Berlin.

Eriksson, B., Helgstrand, E., Johansson, N.G., Larsson, A., Misiorny, A., et al., 1977. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents Chemother. 11, 946–951.

Escarmís, C., Dávila, M., Domingo, E., 1999. Multiple molecular pathways for fitness recovery of an RNA virus debilitated by operation of Muller’s ratchet. J. Mol. Biol. 285, 495–505.

Escarmís, C., Lazaro, E., Arias, A., Domingo, E., 2008. Repeated bottleneck transfers can lead to non-cytocidal forms of a cytopathic virus: implications for viral extinction. J. Mol. Biol. 376, 367–379.

Escrivan-Romero, E., Jimenez de Oya, N., Domingo, E., Saiz, J.C., 2017. Extinction of West Nile virus by favipiravir through lethal mutagenesis. Antimicrob. Agents Chemother. 61, e01400–e01417.

Faci, P., Shimoda, A., Coiana, A., Diaz, G., Peddis, G., et al., 2000. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288, 339–344.

Feigelstock, D.A., Mihalik, K.B., Feinstone, S.M., 2011. Selection of hepatitis C virus resistant to ribavirin. Virol. J. 8, 402.

Feld, J.J., Nanda, S., Huang, Y., Chen, W., Cam, M., et al., 2007. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 46, 1548–1563.

Fernandez-Larsson, R., O’Connell, K., Koumans, E., Patterson, J.L., 1989. Molecular analysis of the inhibitory effect of phosphorylated ribavirin on the vesicular stomatitis virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 33, 1668–1673.

Ferrer-Orta, C., Arias, A., Perez-Luque, R., Escarmís, C., Domingo, E., et al., 2004. Structure of foot-and-mouth disease virus RNA-dependent RNA polymerase and its complex with a template–primer RNA. J. Biol. Chem. 279, 47212–47221.

Ferrer-Orta, C., Sierra, M., Agudo, R., de la Higuera, I., Arias, A., et al., 2010. Structure of foot-and-mouth disease virus mutant polymerases with reduced sensitivity to ribavirin. J. Virol. 84, 6188–6199.

Ferrer-Orta, C., de la Higuera, I., Caridi, F., Sanchez-Aparicio, M.T., Moreno, E., et al., 2015. Multifunctionality of a picornavirus polymerase domain: nuclear localization signal and nucleotide recognition. J. Virol. 89, 6848–6859.

Flavell, R.A., Sabo, D.L., Bandle, E.F., Weissmann, C., 1974. Site-directed mutagenesis: generation of an extracistronic mutation in bacteriophage Q beta RNA. J. Mol. Biol. 89, 255–272.

Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., et al., 2002. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46, 977–981.

Furuta, Y., Komeno, T., Nakamura, T., 2017. Favipiravir (T-705), a broad spectrum inhibitor of viral polymerase. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 93, 449–463.
Gandhi, R.T., Tashima, K.T., Smeaton, L.M., Vu, V., Ritz, J., et al., 2019. Long-term outcomes in a large randomized trial of HIV-1 salvage therapy: 96-week results of AIDS clinical trials group A5241 (OPTIONS). J. Infect. Dis. https://doi.org/10.1093/infdis/jiz281 pii: jiz281.

Galagan, J.E., Selker, E.U., 2004. RIP: the evolutionary cost of genome defense. Trends Genet. 20, 417–423.

Galli, A., Mens, H., Gottwein, J.M., Gerstoft, J., Bukh, J., 2018. Antiviral effect of ribavirin against HCV associated with increased frequency of G-to-A and C-to-U transitions in infectious cell culture model. Sci. Rep. 8, 4619.

Garbelli, A., Radi, M., Falchi, F., Beerms, S., Zanoli, S., et al., 2011. Targeting the human DEAD-box polypeptide 3 (DDX3) RNA helicase as a novel strategy to inhibit viral replication. Curr. Med. Chem. 18, 3015–3027.

Garcia-Perez, J., Staropoli, I., Azoulay, S., Heinrich, J.T., Cascajero, A., et al., 2015. A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity. Retrovirology 12, 50.

Geller, R., Vignuzzi, M., Andino, R., Friedman, J., 2007. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev. 21, 195–205.

Gerotto, M., Sullivan, D.G., Polyaak, S.J., Chemello, L., Cavalletto, L., et al., 1999. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. J. Virol. 73, 7241–7247.

González-López, C., Arias, A., Pariente, N., Gómez-Mariano, G., Domingo, E., 2004. Pre extinction viral RNA can interfere with infectivity. J. Virol. 78, 3319–3324.

Goswami, B.B., Borek, E., Sharma, O.K., Fujitaki, J., Smith, R.A., 1979. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. 89, 830–836.

Graci, J.D., Cameron, C.E., 2002. Quasispecies, error catastrophe, and the antiviral activity of ribavirin. Virology 298, 175–180.

Graci, J.D., Cameron, C.E., 2004. Challenges for the development of ribonucleoside analogues as inducers of error catastrophe. Antivir. Chem. Chemother. 15, 1–13.

Grande-Pérez, A., Sierra, S., Castro, M.G., Domingo, E., Lowenstein, P.R., 2002. Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proc. Natl. Acad. Sci. U.S.A. 99, 12938–12943.

Grande-Pérez, A., Gómez-Mariano, G., Lowenstein, P.R., Domingo, E., 2005a. Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence. J. Virol. 79, 10451–10459.

Grande-Pérez, A., Lázaro, E., Lowenstein, P., Domingo, E., Manrubia, S.C., 2005b. Suppression of viral infectivity through lethal defection. Proc. Natl. Acad. Sci. U.S.A. 102, 4448–4452.

Griesemer, S.B., Kramer, L.D., Van Slyke, G.A., Pata, J.D., Gohara, D.W., et al., 2017. Mutagen resistance and mutation restriction of St. Louis encephalitis virus. J. Gen. Virol. 98, 201–211.

Guedj, D., Piorkowsk, G., Jacquet, F., Madelain, V., Nguyen, T.H.T., 2018. Antiviral efficacy of favipiravir against Ebola virus: a translational study in cynomolgus macaques. PLoS Med. 15, e1002535.

Harki, D.A., Graci, J.D., Korneeva, V.S., Ghosh, S.K., Hong, Z., et al., 2002. Synthesis and antiviral evaluation of a mutagenic and non-hydrogen bonding ribonucleoside analogue: 1-beta-D-Ribofuranosyl-3-nitropyrrrole. Biochemistry 41, 9026–9033.

Harki, D.A., Graci, J.D., Galarraga, J.E., Chain, W.J., Cameron, C.E., et al., 2006. Synthesis and antiviral activity of 5-substituted cytidine analogues: identification of a potent inhibitor of viral RNA-dependent RNA polymerases. J. Med. Chem. 49, 6166–6169.

Harki, D.A., Graci, J.D., Edathil, J.P., Castro, C., Cameron, C.E., et al., 2007. Synthesis of a universal 5-nitroindole ribonucleotide and incorporation into RNA by a viral RNA-dependent RNA polymerase. Chembiochem 8, 1359–1362.

Harris, R.S., Dudley, J.P., 2015. APOBECs and virus restriction. Virology 479–480C, 131–145.

Ho, D.D., 1995. Time to hit HIV, early and hard. N. Engl. J. Med. 333, 450–451.

Holland, J.J., Domingo, E., de la Torre, J.C., Steinhauer, D.A., 1990. Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J. Virol. 64, 3960–3962.

Hopkins, S., Scorneaux, B., Huang, Z., Murray, M.G., Wring, S., et al., 2010. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob. Agents Chemother. 54, 660–672.

Hover, S., Foster, B., Barr, J.N., Mankouri, J., 2017. Viral dependence on cellular ion channels-an emergent antiviral target? J. Gen. Virol. 98, 345–351.

Hultgren, C., Milich, D.R., Welland, O., Sallberg, M., 1998. The antiviral compound ribavirin modulates the Th helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J. Gen. Virol. 79(Pt 10), 2381–2391.

Iranzo, J., Perales, C., Domingo, E., Manrubia, S.C., 2011. Tempo and mode of inhibitor-mutagen antiviral therapies: a multidisciplinary approach. Proc. Natl. Acad. Sci. U.S.A. 108, 16008–16013.
Kato, T., Date, T., Miyamoto, M., Sugiyama, M., Tanaka, Y., Jin, Z., Smith, L.K., Rajwanshi, V.K., Kim, B., Deval, J., 2013. The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5'-triphosphate towards influenza A virus polymerase. PLoS One 8, e68347.

Kanda, T., Yokosuka, O., Imazeki, F., Tanaka, M., Shino, Y., et al., 2004. Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. J. Viral Hepat. 11, 479–487.

Kato, T., Date, T., Miyamoto, M., Sugiyama, M., Tanaka, Y., et al., 2005. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. J. Clin. Microbiol. 43, 5679–5684.

Kim, Y., Lee, C., 2013. Ribavirin efficiently suppresses porcine nidovirus replication. Virus Res. 171, 44–53.

Kiso, M., Takahashi, K., Sakai-Tagawa, Y., Shinya, K., Sakabe, S., et al., 2010. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc. Natl. Acad. Sci. U.S.A. 107, 882–887.

Kolakofsky, D., Roux, L., Garin, C., Ruigrok, R.W., 2005. Paramyxovirus mRNA editing, the “rule of six” and error catastrophe: a hypothesis. J. Gen. Virol. 86, 1869–1877.

Kumar, N., Liang, Y., Parslow, T.G., Liang, Y., 2011. Receptor tyrosine kinase inhibitors block multiple steps of influenza a virus replication. J. Virol. 85, 2818–2827.

Kwong, A.D., Najera, I., Bechtel, J., Bowden, S., Fitzgibbon, J., et al., 2011. Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG. Gastroenterology 140, 755–760.

Lanford, R.E., Chavez, D., Guerra, B., Lau, J.Y., Hong, Z., Kwong, A.D., Najera, I., Bechtel, J., Bowden, S., Fitzgibbon, J., et al., 2011. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J. Virol. 75, 8074–8081.

Le Moing, V., Chene, G., Carrieri, M.P., Alioum, A., Brun-Vezinet, F., et al., 2002. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 16, 21–29.

Lee, C.H., Gilbertson, D.L., Novella, I.S., Huerta, R., Domingo, E., et al., 1997. Negative effects of chemical mutagenesis on the adaptive behavior of vesicular stomatitis virus. J. Virol. 71, 3636–3640.

Levi, L.I., Gnadig, N.F., Beaucourt, S., McPherson, M.J., Baron, B., et al., 2010. Fidelity variants of RNA dependent RNA polymerases uncover an indirect, mutagenic activity of amiloride compounds. PLoS Pathog. 6, e1001163.

Leyssen, P., Balzarini, J., De Clercq, E., Neyts, J., 2005. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J. Virol. 79, 1943–1947.

Leyssen, P., De Clercq, E., Neyts, J., 2006. The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Mol. Pharmacol. 69, 1461–1467.

Li, C., Wang, H., Yuan, T., Woodman, A., Yang, D., et al., 2018. Foot-and-mouth disease virus type O specific mutations determine RNA-dependent RNA polymerase fidelity and virus attenuation. Virology 518, 87–94.

Li, M.J., Kim, J., Li, S., Zaia, J., Yee, J.K., et al., 2005. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCL5 ribozyme, and a nucleolar-localizing TAR decoy. Mol. Ther. 12, 900–909.

Loeb, L.A., Essigmann, J.M., Kazazi, F., Zhang, J., Rose, K.D., et al., 1999. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc. Natl. Acad. Sci. U.S.A. 96, 1492–1497.

Lucas-Hourani, M., Dauzonne, D., Jorda, P., Cousin, G., Lusan, A., et al., 2013. Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. PLoS Pathog. 9, e1003678.

Lutchman, G., Danehower, S., Song, B.C., Liang, T.J., Hoofnagle, J.H., et al., 2007. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 132, 1757–1766.

Maag, D., Castro, C., Hong, Z., Cameron, C.E., 2001. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. 276, 46094–46098.

Martin-Acebes, M.A., Vazquez-Calvo, A., Rincon, V., Mateu, M.G., Sobrino, F., 2011. A single amino acid substitution in the capsid of foot-and-mouth disease virus can increase acid resistance. J. Virol. 85, 2733–2740.

McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiffman, M.L., Lee, W.M., et al., 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339, 1485–1492.

Moreno, H., Gallego, I., Sevilla, N., de la Torre, J.C., Domingo, E., et al., 2011. Ribavirin can be mutagenic for arenaviruses. J. Virol. 85, 7246–7255.

Moreno, H., Grande-Perez, A., Domingo, E., Martin, V., 2012. Arenaviruses and lethal mutagenesis. Prospects for new ribavirin-based interventions. Viruses 4, 2786–2805.

Morii, K., Ikeda, M., Ariumi, Y., Dansako, H., Wakita, T., et al., 2011. Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system. Virus Res. 157, 61–70.

Morrey, J.D., Taro, B.S., Siddharthan, V., Wang, H., Smee, D.F., et al., 2008. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res 80, 377–379.

Mosier, D.E., Picchio, G.R., Gulizia, R.J., Sabbe, R., Poignard, P., et al., 1999. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol. 73, 3544–3550.
Mullins, J.I., Heath, L., Hughes, J.P., Kicha, J., Styrchak, S., Motani, K., Ito, S., Nagata, S., 2015. DNA-mediated cyclic GMP-AMP synthase-dependent and -independent regulation of innate immune responses. J. Immunol. 194, 4914–4923.

Müller, V., Bonhoeffer, S., 2008. Intra-host dynamics and evolution of HIV infections. In: Domingo, E., Parrish, C.R., Holland, J.J. (Eds.), Origin and Evolution of Viruses, second ed. Elsevier, London, pp. 279–320.

Mullins, J.I., Heath, L., Hughes, J.P., Kicha, J., Styrchak, S., et al., 2011. Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KPI461. PLoS One 6, e15135.

Munier-Lehmann, H., Lucas-Hourani, M., Guillou, S., Helynck, O., Zanghi, G., et al., 2015. Original 2-(3-alkoxy-1H-pyrazol-1-yl)pyrimidine derivatives as inhibitors of human dihydroorotate dehydrogenase (DHODH). J. Med. Chem. 58, 860–877.

Nguyen, A.H., Molineux, I.J., Springman, R., Bull, J.J., 2012. Multiple genetic pathways to similar fitness limits during viral adaptation to a new host. Evolution 66, 363–374.

Nowak, M., van Maarseveen, N.M., Boucher, C.A., 1989. Error thresholds of replication and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases. Handb. Exp. Pharmacol. 189, 299–320.

Ning, Q., Brown, D., Parodo, J., Cattral, M., Gorczynski, R., et al., 1998. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J. Immunol. 160, 3487–3493.

Nowak, M., Schuster, P., 1989. Error thresholds of replication in finite populations mutation frequencies and the onset of Muller’s ratchet. J. Theor. Biol. 137, 375–395.

Nyström, K., Wanrooij, P.H., Waldenström, J., Adamek, L., Brunet, S., et al., 2018. Inosine triphosphate pyrophosphohydrolase dephosphorylates ribavirin triphosphate and reduced enzymatic activity potentiates mutagenesis in hepatitis C virus. J. Virol. 92, e01087–18.

Ojosnegros, S., Agudo, R., Sierra, M., Briones, C., Sierra, S., et al., 2008. Topology of evolving, mutagenized viral populations: quasispecies expansion, compression, and operation of negative selection. BMC Evol. Biol. 8, 207.

Ong, H.K., Soo, B.P.C., Chu, K.L., Chao, S.H., 2018. XBP-1, a cellular target for the development of novel anti-viral strategies. Curr. Prot. Pept. Sci. 19, 145–154.

Orgel, L.E., 1963. The maintenance of the accuracy of protein synthesis and its relevance to ageing. Proc. Natl. Acad. Sci. U.S.A. 49, 517–521.

Ortega-Prieto, A.M., Sheldon, J., Grande-Pérez, A., Tejero, H., Gregori, J., et al., 2013. Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis. PLoS One 8, e71039.

Ortiz-Riano, E., Ngo, N., Devito, S., Eggink, D., Munger, J., et al., 2014. Inhibition of arennavirus by A3, a pyrimidine biosynthesis inhibitor. J. Virol. 88, 878–889.

Palmer, B.A., Dimitrova, Z., Skums, P., Crosbie, O., Kenny-Walsh, E., et al., 2014. Analysis of the evolution and structure of a complex intrahost viral population in chronic hepatitis C virus mapped by ultradeep pyrosequencing. J. Virol. 88, 13709–13721.

Pariente, N., Sierra, S., Lowenstein, P.R., Domingo, E., 2001. Efficient virus extinction by combinations of a mutagen and antiviral inhibitors. J. Virol. 75, 9723–9730.

Pariente, N., Airaksinen, A., Domingo, E., 2003. Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J. Virol. 77, 7131–7138.

Perales, C., Domingo, E., 2016. Antiviral strategies based on lethal mutagenesis and error threshold. Curr. Top. Microbiol. Immunol. 392, 323–339.

Perales, C., Mateo, R., Mateu, M.G., Domingo, E., 2007. Insights into RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants. J. Mol. Biol. 369, 3584–3597.

Perales, C., Domingo, E., 2016. Antiviral strategies based on lethal mutagenesis and error threshold. Curr. Top. Microbiol. Immunol. 392, 323–339.

Perales, C., Agudo, R., Domingo, E., 2009a. Counteracting quasispecies adaptability: extinction of a ribavirin-resistant virus mutant by an alternative mutagenic treatment. PLoS One 4, e5554.

Perales, C., Agudo, R., Tejero, H., Manrubia, S.C., Domingo, E., 2009b. Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections. PLoS Pathog. 5, e1000658.

Perales, C., Agudo, R., Manrubia, S.C., Domingo, E., 2011a. Influence of mutagenesis and viral load on the sustained low-level replication of an RNA virus. J. Mol. Biol. 407, 60–78.

Perales, C., Henry, M., Domingo, E., Wain-Hobson, S., Vartanian, J.P., 2011b. Lethal mutagenesis of foot-and-mouth disease virus involves shifts in sequence space. J. Virol. 85, 12227–12240.

Perales, C., Irazo, J., Manrubia, S.C., Domingo, E., 2012. The impact of quasispecies dynamics on the use of therapeutics. Trends Microbiol. 20, 595–603.

Perales, C., Beach, N.M., Sheldon, J., Domingo, E., 2014. Molecular basis of interferon resistance in hepatitis C virus. Curr. Opin. Virol. 8, 38–44.
Perales, C., Gallego, I., De Avila, A.I., Soria, M.E., Gregori, J., et al., 2019. The increasing impact of lethal mutagenesis of viruses. Future Med. Chem. in press.
Pereira-Gomez, M., Sanjuan, R., 2014. Delayed lysis confers resistance to the nucleoside analogue 5-fluorouracil and alleviates mutation accumulation in the single-stranded DNA bacteriophage varphiX174. J. Virol. 88, 5042–5049.
Perelson, A.S., Layden, T.J., 2007. Ribavirin: is it a mutagen for hepatitis C virus? Gastroenterology 132, 2050–2052.
Pfeiffer, J.K., Kirkegaard, K., 2003. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl. Acad. Sci. U.S.A. 100, 7289–7294.
Pfeiffer, J.K., Kirkegaard, K., 2005a. Increased fidelity reduces poliovirus fitness under selective pressure in mice. PLoS Pathog. 1, 102–110.
Pfeiffer, J.K., Kirkegaard, K., 2005b. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J. Virol. 79, 2346–2355.
Pol, S., Couzigou, P., Bourliere, M., Abergel, A., Combis, J.M., et al., 1999. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France. J. Hepatol. 31, 1–7.
Pugach, P., Marozsan, A.J., Ketas, T.J., Landes, E.L., Moore, J.P., et al., 2007. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 361, 212–228.
Pugach, P., Ray, N., Klasse, P.J., Ketas, T.J., Michael, E., et al., 2009. Inefficient entry of virciviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology 387, 296–302.
Qiu, L., Patterson, S.E., Bonac, L.F., Geraghty, R.J., 2018. Nucleobases and corresponding nucleosides display potent antiviral activities against dengue virus possibly through viral lethal mutagenesis. PLoS Negl. Trop. Dis. 12, e0006421.
Querenghi, F., Yu, Q., Billaud, G., Maertens, G., Trepo, C., et al., 2001. Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy. J. Viral Hepat. 8, 120–131.
Rai, D.K., Diaz-San Segundo, F., Campagnola, G., Keith, A., Schafer, E.A., et al., 2017. Attenuation of foot-and-mouth disease virus by engineering viral polymerase fidelity. J. Virol. 91 pii: e00081-17.
Ramachandran, S., Campo, D.S., Dimitrova, Z.E., Xia, G.L., Purdy, M.A., et al., 2011. Temporal variations in the hepatitis C virus intra-host population during chronic infection. J. Virol. 85, 6369–6380.
Rawson, J.M., Heineman, R.H., Beach, L.B., Martin, J.L., Schettler, E.K., et al., 2013. 5,6-dihydro-5-aza-2-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors. Bioorg. Med. Chem. 21, 7222–7228.
Rawson, J.M., Mansky, L.M., 2014. Retroviral vectors for analysis of viral mutagenesis and recombination. Viruses 6, 3612–3642.
Ribeiro, R.M., Bonhoeffer, S., 2000. Production of resistant HIV mutants during antiretroviral therapy. Proc. Natl. Acad. Sci. U.S.A. 97, 7681–7686.
Ruiz-Jarabo, C.M., Ly, C., Domingo, E., de la Torre, J.C., 2003. Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 308, 37–47.
Sacramento, C.Q., De Melo, G.R., De Freitas, C.S., Rocha, N., Hoelz, L.V.B., et al., 2017. The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication. Sci. Rep. 7, 40920.
Sadeghipour, S., Bek, E.J., McMinn, P.C., 2013. Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture. J. Virol. 87, 1759–1769.
Sadowski, J., Hashemi, F.B., 2019. Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs. Cell. Mol. Life Sci. https://doi.org/10.1007/s00018-019-03156-8.
Sanchez-Aparicio, M.T., Rosas, M.F., Sobrino, F., 2013. Characterization of a nuclear localization signal in the foot-and-mouth disease virus polymerase. Virology 444, 203–210.
Sarrazin, C., Zeuzem, S., 2010. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138, 447–462.
Scheidel, L.M., Stollar, V., 1991. Mutations that confer resistance to mycophenolic acid and ribavirin on Sindbis virus map to the nonstructural protein nsP1. Virology 181, 490–499.
Scheidel, L.M., Durbin, R.K., Stollar, V., 1987. Sindbis virus mutants resistant to mycophenolic acid and ribavirin. Virology 158, 1–7.
Schuster, P., 2016. Quasispecies on fitness landscapes. Curr. Top. Microbiol. Immunol. 392, 61–120.
Seiler, P., Senn, B.M., Klennerman, P., Kalinke, U., Hengartner, H., et al., 2000. Additive effect of neutralizing antibody and antiviral drug treatment in preventing virus escape and persistence. J. Virol. 74, 5896–5901.
Severson, W.E., Schmaljohn, C.S., Javadian, A., Jonsson, C.B., Sierra, S., Davila, M., Lowenstein, P.R., Domingo, E., 2003. Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J. Virol. 74, 8316–8323.
Sierra, M., Airaksinen, A., González-López, C., Agudo, R., Arias, A., et al., 2007. Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J. Virol. 81, 2012–2024.

Smith, E.C., Denison, M.R., 2013. Coronaviruses as DNA wannabes: a new model for the regulation of RNA virus replication fidelity. PLoS Pathog. 9, e1003760.

Smith, E.C., Blanc, H., Vignuzzi, M., Denison, M.R., 2013. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog. 9, e1003565.

Smith, E.C., Case, J.B., Blanc, H., Isakov, O., Shomron, N., et al., 2015. Mutations in coronavirus nonstructural protein 10 decrease virus replication fidelity. J. Virol. 89, 6418–6426.

Snell, N.J., 2001. Ribavirin-current status of a broad spectrum antiviral agent. Expert Opin. Pharmacother. 2, 1317–1324.

Solé, R.V., Deisboeck, T.S., 2004. An error catastrophe in cancer? J. Theor. Biol. 228, 47–54.

Sookoian, S., Castano, G., Frider, B., Cello, J., Campos, R., et al., 2007. Mutations in coronavirus nonstructural protein 1 decrease virus replication fidelity. J. Virol. 81, 2012–2024.

Streeter, D.G., Witkowski, J.T., Khare, G.P., Sidwell, R.W., 1999. Evolution in Health and Disease. Oxford University Press, Oxford.

Stern, S.C., 1999. Evolution in Health and Disease. Oxford University Press, Oxford.

Steinmeyer, S.H., Wilke, C.O., 2009. Lateral mutagenesis in a structured environment. J. Theor. Biol. 261, 67–73.

Streeter, D.G., Witkowski, J.T., Khare, G.P., Sidwell, R.W., Bauer, R.J., et al., 1973. Mechanism of action of 1-β-d-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. U.S.A. 70, 1174–1178.

Sullivan, D.G., Bruden, D., Deubner, H., McArthur, S., Chung, M., et al., 2007. Hepatitis C virus dynamics during natural infection are associated with long-term histological outcome of chronic hepatitis C disease. J. Infect. Dis. 196, 239–248.

Swetina, J., Schuster, P., 1982. Self-replication with errors. A model for polynucleotide replication. Biophys. Chem. 16, 329–345.

Takeuchi, N., Hogeweg, P., 2007. Error-threshold exists in fitness landscapes with lethal mutants. BMC Evol. Biol. 7, 15.

Tapia, N., Fernandez, G., Parera, M., Gomez-Mariano, G., Clotet, B., et al., 2005. Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection. Virology 338, 1–8.

Tejero, H., Marin, A., Montero, F., 2011. The relationship between the error catastrophe, survival of the flattest, and natural selection. BMC Evol. Biol. 11, 2.

Tejero, H., Montero, F., Nuño, J.C., 2016. Theories of lethal mutagenesis: from error catastrophe to lethal defection. Curr. Top. Microb. Immunol. 392, 161–179.

Toltzis, P., O’Connell, K., Patterson, J.L., 1988. Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription. Antimicrob. Agents Chemother. 32, 492–497.

Van de Wouw, A.P., Elliot, C.E., Popa, K.M., Idnurm, A., 2019. Analysis of repeat induced point (RIP) mutations in Leptospira maculans indicates variability in the RIP process between fungal species. Genetics 211, 89–104.

Van Vaerenbergh, K., Harrer, T., Schmit, J.C., Carbonez, A., Fontaine, E., et al., 2002. Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients. AIDS Res. Hum. Retroviruses 18, 419–426.

Vazquez-Calvo, A., Martin-Acebes, M.A., Saiz, J.C., Ngo, N., Sobrino, F., et al., 2013. Inhibition of multiplication of the prototypic arenavirus LCMV by valproic acid. Antiviral Res 99, 172–179.

Venkatesan, S., Rosenthal, R., Kanu, N., McGranahan, N., Bartek, J., et al., 2018. Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. Ann. Oncol. 29, 563–572.

Vermehren, J., Sarrazin, C., 2011. New HCV therapies on the horizon. Clin. Microbiol. Infect. 17, 122–134.

Vidalain, P.O., Lucas-Hourani, M., Helynck, O., Tangy, F., Munier-Lehmann, H., 2015. Stimulation of the antiviral innate immune response by pyrimidine biosynthesis inhibitors: a surprise of phenotypic screening. Med. Sci. (Paris) 31, 98–104.

Vignuzzi, M., Stone, J.K., Arnold, J.J., Cameron, C.E., Andino, R., 2006. Quasispecies diversity determines pathogenicity. PLoS Pathog. 2, e1000493.

Von Kleist, M., Menz, S., Stocker, H., Arasteh, K., Schutte, C., et al., 2011. HIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirs. PLoS One 6, e18204.
Warmbrod, K.L., Patterson, E.I., Kautz, T.F., Stanton, A., Rockx-Brouwer, D., et al., 2019. Viral RNA-dependent RNA polymerase mutants display an altered mutation spectrum resulting in attenuation in both mosquito and vertebrate hosts. PLoS Pathog. 15, e1007610.

Webster, R.G., Kawaoka, Y., Bean, W.J., Beard, C.W., Brugh, M., 1985. Chemotherapy and vaccination: a possible strategy for the control of highly virulent influenza virus. J. Virol. 55, 173–176.

Webster, R.G., Kawaoka, Y., Bean, W.J., 1986. Vaccination as a strategy to reduce the emergence of amantadine- and rimantadine-resistant strains of A/Chick/Pennsylvania/83 (H5N2) influenza virus. J. Antimicrob. Chemother. 18, 157–164.

Williams, P.D., 2009. Darwinian interventions: taming pathogens through evolutionary ecology. Trends Parasitol. 26, 83–92.

Wray, S.K., Gilbert, B.E., Noall, M.W., Knight, V., 1985. Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antiviral Res 5, 29–37.

Young, K.C., Lindsay, K.L., Lee, K.J., Liu, W.C., He, J.W., et al., 2003. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 38, 869–878.

Yu, H., Eritja, R., Bloom, L.B., Goodman, M.F., 1993. Ionization of bromouracil and fluorouracil stimulates base mispairing frequencies with guanine. J. Biol. Chem. 268, 15935–15943.

Zeng, J., Wang, H., Xie, X., Yang, D., Zhou, G., et al., 2013. An increased replication fidelity mutant of foot-and-mouth disease virus retains fitness in vitro and virulence in vivo. Antiviral Res 100, 1–7.

Zeng, J., Wang, H., Xie, X., Li, C., Zhou, G., et al., 2014. Ribavirin-resistant variants of foot-and-mouth disease virus: the effect of restricted quasispecies diversity on viral virulence. J. Virol. 88, 4008–4020.

Zhang, Y., Jamaluddin, M., Wang, S., Tian, B., Garofalo, R.P., et al., 2003. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J. Virol. 77, 5933–5947.

Zhou, S., Liu, R., Baroudy, B.M., Malcolm, B.A., Reyes, G.R., 2003. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 310, 333–342.